

Curriculum Vitae

Meena Jaggi, PhD

Professor (Tenured)

Department of Immunology and Microbiology

School of Medicine

University of Texas Rio Grande Valley

McAllen, TX 78503, USA

E-mail: meena.jaggi@utrgv.edu

Ph: 901-216-3416

EDUCATION:

Ph.D (December 1998) Cell Biology/Reproductive Endocrinology “*In-vitro* Studies on First Trimester Human Trophoblasts” Central Drug Research Institute (CDRI), Lucknow, India

M.Sc (July 1990) Zoology (With specialization in cytogenetics) University of Allahabad, India

B.Sc (July 1988) Botany, Chemistry, Zoology University of Allahabad, India

HONORS/AWARDS:

1. Qualified GATE Examination 1993 (Discipline-General Sciences) Conducted by Ministry of Human Resource Development, India.
2. Junior Research Fellowship (1993) awarded by Ministry of Health and family welfare, G.O.I. at C.D.R.I. Lucknow, India.
3. Senior Research Fellowship (1995) awarded by Ministry of Health and family welfare, G.O.I. at C.D.R.I. Lucknow, India.
4. Received an Internal Research Award (4/18/2006) from Sanford School of Medicine of The University of South Dakota for \$5,000.
5. Argus Leader, Sioux Falls Nov, 3, 2008 “*Researcher spending time in rehab*”.
6. Sanford Health, Sioux Falls, Mach, 17, 2009, “*Sanford Researcher Published in Top Cancer Research Journal*”
7. YWCA, Sioux Falls, April 2, 2009, Tribute to women “*Science and Technology*”
8. Argus Leader, Friday, April 3, 2009, “*Tribute to Women*”
9. Interviewed in the, May, 20, 2009, Q&A of the Sioux Falls Business Journal, “*Jaggi’s cancer research help put pieces together to save lives*”

10. Sioux Falls Woman, June/July 2009, Vol 7, Issue 4, A tribute to Women YWCA, of Sioux Falls Honors 10 Inspirational Women
11. Dean's Enhancement Program for Seed Research Grants, 2013 - Based on the recommendation by the Research Committee, the Dean has approved your application on MTA1 for funds from the Dean's Enhancement Program for Seed Research Grants at a funding level of \$15,000, University of Tennessee Health Science Center, 881 Madison Ave., Ste. 264 Memphis, TN, 38163
12. Dean's Enhancement Program for Seed Research Grant, 2013-14 - Based on the recommendation by the Research Committee, the Dean has approved your application for funds from the Dean's Enhancement Program for Research Equipment at a funding level of \$23,163 - Request for Proposals for Research Equipment Purchase of the Purchase of BD Accuri™ C6 Flow Cytometer Instrument.
13. Meena Jaggi research work highlighted on Center to reduce Cancer Health Disparities (CRCHD) Spotlight for January 2015. Please find our news regarding on NIH website (CRCHD). http://crchd.cancer.gov/news/spotlights/grantee-spotlights_jaggi.html
14. Dean's Instrument Grant – Based on the recommendation by the Research Committee, the Dean has approved your application for the purchase of UVP Biospectrum 810 equipment from the Dean's Enhancement Program for Research Equipment at a funding level of \$15,000.
15. New Grant Support Fund, UTHSC- Based on the several competitive grants submitted our grant was funded for two years for the amount of \$25,000.
16. Dean's Instrument Grant – Based on the recommendation by the Research Committee, the Dean has approved our application for the purchase of Xcelligence RTCA-DP equipment from the Dean's Enhancement Program for Research Equipment at a funding level of \$19,271.60.
17. **Dean's Enhancement Program for Seed Research Grants**, 2016 – Based on the recommendation by the review committee, Dean has approved our application on PKD1 mediated regulation of microRNA-21 for the funding level of \$15,000.
18. **CORNET Clinical Award** 2018 for “*Role of LncRNA- MALAT1 in Colorectal Cancer Health Disparity*”.

SOCIETY MEMBERSHIPS:

Active member of The American Society for Cell Biology since 2002

Active member of The American Association for Cancer Research since 2003

South Dakota Academy of Science (SDAS) 2003

Nature 2009

UNIVERSITY (AND COLLEGE) APPOINTMENTS:

07/01/13 to present: Associate Professor
Department of Pharmaceutical sciences
College of Pharmacy and Cancer Research Center
University of Tennessee Health Science Center (UTHSC)
19S Manassas Avenue
Memphis, Tennessee, 38163

PRACTICE/PROFESSIONAL EXPERIENCE:

2019-Present. Professor, Department of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78503, USA

2013-2019, Associate Professor, Cancer Research Center, Department of Pharmaceutical Sciences, The University of Tennessee Health Science Center, Memphis, TN, USA

2008- June 2013, **Associate Scientist**, Cancer Biology Research Center, Sanford Research/USD, Sioux Falls, SD, USA

2011-June 2013, **Associate Professor**, Obstetrics & Gynecology, and Basic Biomedical Sciences Division, The University of South Dakota Sanford School of Medicine and Health Science, Sioux Falls, SD, USA

2006-2010, **Assistant Professor**, Obstetrics & Gynecology, and Basic Biomedical Sciences Division, The University of South Dakota Sanford School of Medicine and Health Science, Sioux Falls, SD, USA

2005 Dec- 2008-**Research Scientist**, Signal Transduction Institute, South Dakota Health Research Foundation, Sioux Falls, SD, USA

2002-2005-**Instructor**, Department of Surgery, Nebraska Medical Center, Omaha, NE, USA

2001-2002- **Postdoctoral Research Associate**, Department of Oral Biology, Nebraska Medical Center Omaha, NE, USA

1999–2001- **Postdoctoral Fellow**, Department of Biology, University of Toledo, Toledo, OH, USA

1998 –1999- **Research Associate**, Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), New Delhi, INDIA

1995-1998- **Senior Research Fellow**, Department of Endocrinology, CDRI, Lucknow, INDIA

1993-1995- **Junior Research Fellow**, Department of Endocrinology, CDRI, Lucknow, INDIA

TEACHING EXPERIENCE:

One MD/PhD student was trained in my lab.

Two graduate students are being directed for PhD degrees. Additionally, one other PhD student is receiving input for her PhD as a committee member.

I am also involved in mentoring a junior faculty members and postdocs.

VISITING PROFESSORSHIPS AND INVITED LECTURES:

1. *Cell adhesion assembly in cancer progression*: Invited seminar at Industrial Toxicology Research Center (ITRC), Lucknow, India (January 1, 2008)
2. *Bryostatins suppresses β -catenin transcription activity by PKD1 activation in prostate cancer cells*. 2nd International Symposium on Translational Cancer Research: Natural Products and Cancer, Lonavala (Mumbai), India, December 11, 2007.
3. *Protein Kinase D and β -catenin Cross-Talk in Cancer*. Department of Biology, University of South Dakota, Vermillion, Oct 22, 2007
4. *E-cadherin, β -catenin and plakoglobin dysregulation and its clinical significance in cervical cancers* Frontiers in Women's Health: Pioneering Researchers in South Dakota, May 16, 2007
5. *Protein Kinase D1 and β -catenin signaling in prostate cancer*. Department of Pharmaceutical Sciences, College of Pharmacy, South Dakota State University, Brookings, May 4, 2007
6. *Effect of Curcumin on signaling pathways in cancer*. South Dakota Academy of Science Signal Transduction Symposium, Brookings, April 13 2007
7. *Introduction to Flow Cytometry*. Cardiovascular Research Institute Seminar Series, February 2007.
8. *Basic Information on India and Herbal Medicine*. The Wegner Health Science Information Center Diversity Dialogue "INDIA", October 2006.
9. *Aberrant expression of E-cadherin and β -catenin in gynecological cancers*. Frontiers in Women's Health: Pioneering Researchers in South Dakota, May 15, 2006.
10. *Aberrant Expression of N-cadherin Correlates with Gleason Grade in Prostate Cancer* Sioux Valley Hospital Tumor Conferences Tuesday, April 25, 2006
11. *Protein Kinase D1 (PKD1/PKC μ) and Cell Adhesion Molecules Cross-talk in Prostate Cancer*, Cardiovascular Research Institute Seminar Series, 2006.

EDITORIAL APPOINTMENTS:

Member Editorial Board:

- 1) Cancer Research
- 2) Oncotarget
- 3) Clinical Cancer Research
- 4) Molecular Cancer Therapeutics
- 5) PLOS One
- 6) Molecular Cancer Research
- 7) Gene
- 8) Nanoscale Research Letters
- 9) Journal of Cellular Biochemistry
- 10) BMC Pharmacology
- 11) Journal for Functional Foods
- 12) Drug design, development and therapy
- 13) Expert Opinion on Drug Metabolism and Toxicology

COMMITTEES AND OFFICES HELD:

1. Basic Biomedical Science Graduate Student Committee (2008 to 2012)
2. Health Affairs Informatics Committee, 2010
3. Internal advisory committee Cancer COBRE grant (Sanford Research) 2012-2013

RESIDENTS/FELLOWS/GRADUATE STUDENTS TRAINED:

Assistant Professor

1. Sheema Khan
2. Bilal Hafeez
3. Manish Tripathi

Post-Doctoral Fellow

1. Vasudha Sundram, PhD.
2. Rishi Kumar Gara, PhD
3. Mohammed Sikander, PhD
4. Shabnam Malik, PhD
5. Vivek Kashyap, PhD
6. Prashanth Bhushetty, PhD
7. Aditya Ganju, PhD

Students:

Joshua E Hughes BS (2006, Summer Student, 2009, Graduate Summer Student and later enrolled for MD/ PhD program)

Sonam Kumari, MS (2014, PhD Student)

Saini Setua, MS (2014, PhD Student)

Andrew E. Massey (2016, PhD student)

Kyle Doxtater (2016, PhD student)

Nirnoy Dan (2016, PhD student)

Pragathi Gunnam Reddy (2017, PhD student)

Kamalika Samanta (2017, PhD student)

Mehdi Chaib (2017, PhD student)

Fatemeh Keramatnia (2017, PhD student)

Advait Shetty (2017, PhD student)

Chidi Zacheaus (2017, PhD student)

Aditya Ganju (2017, PhD student, graduated)

Medical Residents/MDs

Namita Vinayek, MD (2005, USD Medical Resident)

Preethi Prakash, MD (2006, Sanford Hospitalist)

Deepti Haskoppal, MD (2007, Sanford Hospital)

Research Associates:

1. Katrina Dunham, RA (Jan 2006 to August 2007)
2. Kristina Wattier, RA (July 2006 to July 2007)
3. Tyler Jepperson, RA (September 2007-December 2008)
4. Sarah Radel, RA (March 2007-2011)

Summer Students:

1. Lanna (2016, Summer Student)
2. Nia Johnson (2015, Summer Student)
3. Renn Lovett (2015, Summer Student)
4. Bhavin Chauhan (2013-2014, Summer Student)
5. Ankita Shah (2013, Summer Student)
6. Nikki Bauer (2012, Summer Student)
7. Greg Gerrish (2007, Summer Student)
8. Kate Ahlers (2007, BRIN Summer Student)
9. Seth Harris (2009, Summer Student)

Achievements:

1. **CORNET Clinical Award 2018** for “*Role of LncRNA- MALAT1 in Colorectal Cancer in Health Disparity*”.
2. **AAISCR-Legacy Immigration Training Scholarship Award for Career Advancement-2018 to Vivek Kashyap**, Presented at 25th AAISCR annual meeting, Chicago, IL, April 16, 2018.
3. **UTHSC Postdoctoral Winter Travel Award to Vivek Kashyap** for attending AACR Annual Meeting 2018, Chicago. April 14-18, 2018.
4. **Travel award to Sonam Kumari** for presenting the poster at AACR Annual Meeting 2018, Chicago. April 14-18, 2018, "**Aberrant expression of Protein Kinase D1 influences metabolic reconditioning in pancreatic cancer**".
5. **Travel Award to Saini Setua** for the AACR 2018 abstract titled as “**Therapeutic intervention for pancreatic cancer using autologous exosomes**”.
6. **Dean Research Seed Grant 2016-2017, UTHSC** awarded to Meena Jaggi
7. **Kyle Doxtater (PhD student)** received Best poster presentation at Graduate Research Day, 2017 UTHSC.
8. **New Grant Support Fund 2016-2017, UTHSC** awarded to Meena Jaggi.
9. **Dean’s Enhancement Program for Seed Research Grant, 2016, UTHSC**, awarded to Meena Jaggi.
10. **Dean’s Enhancement Program for Research Equipment 2016** awarded to Meena Jaggi.
11. **UTHSC Graduate Travel Award 2016** to Aditya Ganju for the poster titled “Ormeloxifene, a novel pharmacological activator of PKD1 enhances docetaxel sensitivity in prostate cancer” for American Association of Cancer Research (AACR).
12. **UTHSC Postdoctoral Travel Award 2016** to Mohammed Sikander for the poster titled “Novel cucurbitacin analogue Cuc D exhibits potent anti-cancer activity in cervical cancer” for American Association of Cancer Research (AACR).
13. **First Prize Poster Award 2015** to Aditya Ganju for the poster titled as “Ormeloxifene attenuate Wnt/ β -catenin signaling in Colon Cancer by modulation of PKD1 and Glycolytic pathways”
14. **First Prize Poster Award 2015** to Saini Setua for the poster titled as “Restitution of tumor suppressor miR-145 using magnetic nanoparticles inhibits pancreatic cancer.”
15. **Best Poster Presentation Award, 2014 UTHSC PhDA Postdoc Research Day Meeting:** Sheema Khan, Murali M. Yallapu, Sonam Kumari, Aditya Ganju, Swathi Balakrishna, Stephen W. Behrman, Nadeem Zafar, Meena Jaggi, Subhash C. Chauhan. Attenuation of Pancreatic Cancer Stemness and Growth by a Novel Magnetic Nanoparticle Formulation. *2014 PhDA Meeting Poster session, UTHSC Postdoc Research Day (Dec 10, 2014), Memphis, TN.*

16. **UTHSC PhDA Winter Travel Award, 2014.** Sheema Khan, Murali M. Yallapu, Sonam Kumari, Aditya Ganju, Swathi Balakrishna, Stephen W. Behrman, Nadeem Zafar, Meena Jaggi, Subhash C. Chauhan. Attenuation of Pancreatic Cancer Stemness and Growth by a Novel Magnetic Nanoparticle Formulation. *2014 PhDA Meeting Poster session, UTHSC Postdoc Research Day (Dec 10, 2014), Memphis, TN.*
17. **Dean's Enhancement Program for Seed Research Grants, 2013** Based on the recommendation by the Research Committee, the Dean has approved your application on MTA1 for funds from the Dean's Enhancement Program for Seed Research Grants at a funding level of \$15,000, University of Tennessee Health Science Center, 881 Madison Ave., Ste. 264 Memphis, TN 38163.
18. **Dean's Enhancement Program for Seed Research Grant, 2013** Based on the recommendation by the Research Committee, the Dean has approved your application for funds from the Dean's Enhancement Program for Research Equipment at a funding level of \$23,163.
19. **UTHSC Outstanding Postdoctoral fellow Achievement Award.** Sheema Khan A junior UTHSC postdoc fellow for demonstrating consistently high achievement in her field of postdoctoral research 2014-2015.
20. Joshua E. Hughes, summer student in lab is selected for USD MD/PhD program.
21. Greg Gerrish summer student in lab was provided research experience received admission in USD MD program.
22. Kate Ahlers, BRIN summer student presented poster at the end of her training.
23. Kristina Wattier, Research Associate applied and received admission in USD MD program.
24. Dr. Namita Vinayek research trainee has successfully obtained oncology fellowship.

Intern/Volunteers (while at UTHSC)

25. Swathi Balakrishna, MS
19. Mehreen Naaz Khan, MD

RESEARCH AND OTHER EXTERNAL SUPPORT:

- Dean's Enhancement Program for Research Seed Grants, UTHSC (PI –Jaggi) 07/01/2016-06/30/2017
- New Grant Support Fund, UTHSC (PI-Jaggi) 11/1/15 – 10/31/17
- 1R01CA206069-01 (PI: Chauhan; Jaggi-Co-I) 06/01/2016-05/31/2021

NIH-NCI R01

Development of Targeted Nanotechnology Platform for Pancreatic Cancer
To develop efficient targeted therapeutic formulation for pancreatic cancer
Overlap: None.

1R01CA199708-01A1 (PI: Chauhan; **Jaggi-Co-I**) 06/01/2016-05/31/2021

NIH-NCI R01

MUC13 Targeted Novel Paclitaxel Nanoparticle Formulation for Pancreatic Cancer
To delineate MUC13 targeted therapeutics for Pancreatic Cancer
Overlap: None.

1R01CA204552-01 (PI: Chauhan; **Jaggi-Co-I**) 06/01/2016-05/31/2021

NIH-NCI R01

MUC13 in Colorectal Cancer

To examine the role of MUC13 in colorectal cancer in African American, American Indian and
Caucasian. Overlap: None.

Dean's Enhancement Program for Seed Research Grants, UTHSC **(PI- Jaggi)**

07/01/2015 - 06/31/2016

Dean's Enhancement Program for Research Equipment, UTHSC **(PI-Jaggi)**

07/01/2015 - 06/31/2016

Brief Title A Novel Therapeutic Modality for Advanced Stage Prostate Cancer
Treatment (PC130870)

Name of PI*: Subhash C. Chauhan

Sponsor/Funding source: Department of Defense (DOD) Award start and end dates:
07/01/2014-06/30/2017

Your Role: **Co-PI** % effort on grant: 10%

Award amount for this academic year: \$125,000 Award amount to the
College: \$125,000 Total award: \$550,000

Brief Title Aspects of MUC13 Mucin in Cancer (R01 CA142736-01A1 NCI/NIH)

Name of PI*: Subhash C. Chauhan

Sponsor/Funding source: NCI/NIH Award start and end dates: 07/01/10 - 06/30/14

Your Role: Co-I % effort on grant: 10%

Award amount for this academic year: \$200,000 Award amount to the
College: \$200,000 Total award: 1.1 M

Brief Title **Etiology of Aggressive Cervical Cancer Health Disparity in American Indian
Women**

Name of PI*: Subhash C. Chauhan

Sponsor/Funding source: NCI/NIH Award start and end dates: 06/21/12 - 06/20/17

Your Role: **Co-PI** % effort on grant: 20%

Award amount for this academic year: \$207,000 Award amount to the
College: \$207,000 Total award: 1.5M

Subhash C. Chauhan and Deepak Kumar, **Co-editors:** Meena Jaggi and Maria C. Bell. Research Signpost Publications, PP 143-162

9. Yallapu MM., **Jaggi M** and Chauhan SC. Design of Nanoparticle Mediated Targeted Drug Delivery: Ovarian Cancer Perspective “*Current Advances in Gynecological Oncology*” **Editor(s):** Dr. Subhash C. Chauhan and Deepak Kumar, **Co-editors:** Meena Jaggi and Maria C. Bell. Research Signpost Publications, PP 209-244
10. Chauhan SC., Kumar D, Bell MC, Verma M, and **Jaggi M**. Current Trends in Ovarian Cancer Diagnostics and Therapeutics. “*Current Advances in Gynecological Oncology*” **Editor(s):** Dr. Subhash C. Chauhan and Deepak Kumar, **Co-editors:** Meena Jaggi and Maria C. Bell. Research Signpost Publications, PP 1-28
11. **Jaggi M.**, Basak S., Das C. Hormonal regulation of integrin expression in mouse blastocyst during implantation. American Journal of Reproductive immunology, 1998, Vol 40, p 264
12. **Jaggi M.**, Mehrotra P. K., Maitra S. C., Agarwal S. L., Das K., and Kamboj V. P. Ultrastructure of Cellular Components of Human Trophoblasts during Early Pregnancy. 1994, Placenta, Vol. 15A.34.

Book(s) Edited

1. *Current Advances in Gynecological Oncology*. **Editor(s):** Dr. Subhash C. Chauhan and Deepak Kumar, **Co-editor(s): Meena Jaggi** and Maria C. Bell, Publisher: Research Signpost/Transworld Research Network

PEER-REVIEWED JOURNAL ARTICLES:

1. Massey AE, Sikander M, Chauhan N, Kumari S, Setua S, Shetty AB, Mandil H, Kashyap VK, Khan S, **Jaggi M**, Yallapu MM, Hafeez BB, Chauhan SC. Next-generation paclitaxel-nanoparticle formulation for pancreatic cancer treatment. *Nanomedicine*. 2019 Jun 4;102027. doi: 10.1016/j.nano.2019.102027. PMID: 31170509.
2. Khan S, Setua S, Kumari S, Dan N, Massey A, Hafeez BB, Yallapu MM, Stiles ZE, Alabkaa A, Yue J, Ganju A, Behrman S, **Jaggi M**, Chauhan SC. Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine therapeutic response in pancreatic cancer. *Biomaterials*. 2019 Jul;208:83-97. doi:10.1016/j.biomaterials.2019.04.005. Epub 2019 Apr 8. PubMed PMID: 30999154.
3. Sikander M, Malik S, Chauhan N, Khan P, Kumari S, Kashyap VK, Khan S, Ganju A, Halaweish FT, Yallapu MM, **Jaggi M**, Chauhan SC. Cucurbitacin D Reprograms Glucose Metabolic Network in Prostate Cancer. *Cancers (Basel)*. 2019 Mar 14;11(3). pii:E364. doi: 10.3390/cancers11030364. PubMed PMID: 30875788; PubMed Central PMCID: PMC6469021.

4. Chowdhury P, Nagesh PKB, Hatami E, Wagh S, Dan N, Tripathi MK, Khan S, Hafeez BB, Meibohm B, Chauhan SC, **Jaggi M**, Yallapu MM. Tannic acid-inspired paclitaxel nanoparticles for enhanced anticancer effects in breast cancer cells. *J Colloid Interface Sci.* 2019 Feb 1;535:133-148. doi: 10.1016/j.jcis.2018.09.072. Epub 2018 Sep 22. PubMed PMID: 30292104.
5. Tripathi MK, Zacheaus C, Doxtater K, Keramatnia F, Gao C, Yallapu MM, **Jaggi M**, Chauhan SC. Z Probe, An Efficient Tool for Characterizing Long Non-Coding RNA in FFPE Tissues. *Noncoding RNA.* 2018 Sep 5;4(3). pii: E20. doi:10.3390/ncrna4030020. PubMed PMID: 30189670; PubMed Central PMCID: PMC6162476.
6. Nagesh PKB, Chowdhury P, Hatami E, Boya VKN, Kashyap VK, Khan S, Hafeez BB, Chauhan SC, **Jaggi M**, Yallapu MM. miRNA-205 Nanoformulation Sensitizes Prostate Cancer Cells to Chemotherapy. *Cancers (Basel).* 2018 Aug 25;10(9). pii: E289. doi: 10.3390/cancers10090289. PubMed PMID: 30149628; PubMed Central PMCID: PMC6162422.
7. Stiles ZE, Khan S, Patton KT, **Jaggi M**, Behrman SW, Chauhan SC. Transmembrane mucin MUC13 distinguishes intraductal papillary mucinous neoplasms from non-mucinous cysts and is associated with high-risk lesions. *HPB (Oxford).* 2018 Aug 13. pii: S1365-182X(18)32694-7. doi: 10.1016/j.hpb.2018.07.009. [Epub ahead of print] PubMed PMID: 30115565.
8. Chowdhury P, Nagesh PKB, Khan S, Hafeez BB, Chauhan SC, **Jaggi M**, Yallapu MM. Development of polyvinylpyrrolidone/paclitaxel self-assemblies for breast cancer. *Acta Pharm Sin B.* 2018 Jul;8(4):602-614. doi: 10.1016/j.apsb.2017.10.004. Epub 2017 Dec 10. PubMed PMID: 30109184; PubMed Central PMCID: PMC6090082.
9. Hatami E, Nagesh PKB, Chowdhury P, Chauhan SC, **Jaggi M**, Samarasinghe AE, Yallapu MM. Tannic Acid-Lung Fluid Assemblies Promote Interaction and Delivery of Drugs to Lung Cancer Cells. *Pharmaceutics.* 2018 Aug 1;10(3). pii: E111. doi: 10.3390/pharmaceutics10030111. PubMed PMID: 30071698; PubMed Central PMCID: PMC6161105.
10. Almadadi HM, Nagesh PKB, Sahay P, Bhandari S, Eckstein EC, **Jaggi M**, Chauhan SC, Yallapu MM, Pradhan P. Optical study of chemotherapy efficiency in cancer treatment via intracellular structural disorder analysis using partial wave spectroscopy. *J Biophotonics.* 2018 Dec;11(12):e201800056. doi: 10.1002/jbio.201800056. Epub 2018 Sep 26. PubMed PMID: 29869394.
11. Tripathi MK, Doxtater K, Keramatnia F, Zacheaus C, Yallapu MM, **Jaggi M**, Chauhan SC. Role of lncRNAs in ovarian cancer: defining new biomarkers for therapeutic purposes.

- Drug Discov Today. 2018 Apr 23. pii: S1359-6446(18)30071-0. doi: 10.1016/j.drudis.2018.04.010. [Epub ahead of print] Review. PubMed PMID: 29698834.
12. Dan N, Setua S, Kashyap VK, Khan S, **Jaggi M**, Yallapu MM, Chauhan SC. Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications. *Pharmaceuticals (Basel)*. 2018 Apr 9;11(2). pii: E32. doi: 10.3390/ph11020032. Review. PubMed PMID: 29642542.
 13. Nagesh PKB, Hatami E, Chowdhury P, Kashyap VK, Khan S, Hafeez BB, Chauhan SC, **Jaggi M**, Yallapu MM. Tannic Acid Induces Endoplasmic Reticulum Stress-Mediated Apoptosis in Prostate Cancer. *Cancers (Basel)*. 2018 Mar 7;10(3). pii: E68. doi: 10.3390/cancers10030068. PubMed PMID: 29518944; PubMed Central PMCID: PMC5876643.
 14. Kumari S, Khan S, Gupta SC, Kashyap VK, Yallapu MM, Chauhan SC, **Jaggi M**. MUC13 contributes to rewiring of glucose metabolism in pancreatic cancer. *Oncogenesis*. 2018 Feb 22;7(2):19. doi: 10.1038/s41389-018-0031-0. PubMed PMID: 29467405; PubMed Central PMCID: PMC5833644.
 15. Ganju A, Chauhan SC, Hafeez BB, Doxtater K, Tripathi MK, Zafar N, Yallapu MM, Kumar R, **Jaggi M**. Protein kinase D1 regulates subcellular localisation and metastatic function of metastasis-associated protein 1. *Br J Cancer*. 2018 Feb 20;118(4):587-599. doi: 10.1038/bjc.2017.431. Epub 2018 Feb 20. PubMed PMID: 29465084; PubMed Central PMCID: PMC5830591.
 16. Khan S, Zafar N, Khan SS, Setua S, Behrman SW, Stiles ZE, Yallapu MM, Sahay P, Ghimire H, Ise T, Nagata S, Wang L, Wan JY, Pradhan P, **Jaggi M**, Chauhan SC. Clinical significance of MUC13 in pancreatic ductal adenocarcinoma. *HPB (Oxford)*. 2018 Jan 15. pii: S1365-182X(17)31184-X. doi: 10.1016/j.hpb.2017.12.003. [Epub ahead of print] PubMed PMID: 29352660.
 17. Sahay P, Ganju A, Almadadi HM, Ghimire HM, Yallapu MM, Skalli O, **Jaggi M**, Chauhan SC, Pradhan P. Quantification of photonic localization properties of targeted nuclear mass density variations: Application in cancer-stage detection. *J Biophotonics*. 2017 Dec 9. doi: 10.1002/jbio.201700257. [Epub ahead of print] PubMed PMID: 29222925.
 18. Setua S, Khan S, Doxtater K, Yallapu MM, Jaggi M, Chauhan SC. miR-145: Revival of a Dragon in Pancreatic Cancer. *J Nat Sci*. 2017 Mar;3(3). pii: e332. PubMed PMID: 28616589; PubMed Central PMCID: PMC5467535.
 19. Chowdhury P, Roberts AM, Khan S, Hafeez BB, Chauhan SC, Jaggi M, Yallapu MM. Magnetic nanoformulations for prostate cancer. *Drug Discov Today*. 2017 Aug;22(8):1233-1241. doi: 10.1016/j.drudis.2017.04.018. Epub 2017 May 16. Review. PubMed PMID: 28526660; PubMed Central PMCID: PMC5565688.

20. Karuri AR, Kashyap VK, Yallapu MM, Zafar N, Kedia SK, Jaggi M, Chauhan SC. Disparity in rates of HPV infection and cervical cancer in underserved US populations. *Front Biosci (Schol Ed)*. 2017 Jun 1;9:254-269. Review. PubMed PMID: 28410118.
21. Sikander M, Hafeez BB, Malik S, Alsayari A, Halaweish FT, Yallapu MM, Chauhan SC, **Jaggi M***. Cucurbitacin D exhibits potent anti-cancer activity in cervical cancer. *Sci Rep*. 2016 Nov 8;6:36594. doi: 10.1038/srep36594. PubMed PMID: 27824155; PubMed Central PMCID: PMC5100479.
22. Ganju A, Khan S, Hafeez BB, Behrman SW, Yallapu MM, Chauhan SC, **Jaggi M***. miRNA nanotherapeutics for cancer. *Drug Discov Today*. 2017 Feb;22(2):424-432. doi:10.1016/j.drudis.2016.10.014. Epub 2016 Nov 1. Review. PubMed PMID: 27815139; PubMed Central PMCID: PMC5309208.
23. Karuri AR, Kashyap VK, Yallapu MM, Zafar N, Kedia SK, **Jaggi M**, Chauhan SC. Disparity in rates of HPV infection and cervical cancer in underserved US populations. *Front Biosci (Schol Ed)*. 2017 Jun 1;9:254-269. PubMed PMID:28410118.
24. Boya VN, Lovett R, Setua S, Gandhi V, Nagesh PK, Khan S, **Jaggi M**, Yallapu MM, Chauhan SC. Probing mucin interaction behavior of magnetic nanoparticles. *J Colloid Interface Sci*. 2017 Feb 15;488: 258-268. doi: 10.1016/j.jcis.2016.10.090. Epub 2016 Nov 1. PubMed PMID: 27837716.
25. Setua S, Khan S, Yallapu MM, Behrman SW, Sikander M, Khan SS, **Jaggi M**, Chauhan SC. Restitution of Tumor Suppressor MicroRNA-145 Using Magnetic Nanoformulation for Pancreatic Cancer Therapy. *J Gastrointest Surg*. 2017 Jan;21(1):94-105. doi:10.1007/s11605-016-3222-z. Epub 2016 Aug 9. PubMed PMID: 27507554; PubMed Central PMCID: PMC5336381
26. Nagesh PK, Johnson NR, Boya VK, Chowdhury P, Othman SF, Khalilzad-Sharghi V,
27. Hafeez BB, Ganju A, Khan S, Behrman SW, Zafar N, Chauhan SC, **Jaggi M***, Yallapu MM. PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer. *Colloids Surf B Biointerfaces*. 2016 Mar 26;144:8-20. doi: 10.1016/j.colsurfb.2016.03.071. [Epub ahead of print] PubMed PMID: 27058278.
28. Zaman MS, Chauhan N, Yallapu MM, Gara RK, Maher DM, Kumari S, Sikander M, Khan
29. S, Zafar N, **Jaggi M**, Chauhan SC. Curcumin Nanoformulation for Cervical Cancer Treatment. *Sci Rep*. 2016 Feb 3;6:20051. doi: 10.1038/srep20051. PubMed PMID: 26837852; PubMed Central PMCID: PMC4738284.
30. Khan S, **Jaggi M**, Chauhan SC. Revisiting stroma in pancreatic cancer. *Oncoscience*. 2015 Aug 21;2(10):819-20. *eCollection* 2015. PubMed PMID: 26682261; PubMed Central PMCID: PMC4671936.

31. Yallapu MM, Nagesh PK, **Jaggi M**, Chauhan SC. Therapeutic Applications of Curcumin Nanoformulations. *AAPS J*. 2015 Nov;17(6):1341-56. doi: 10.1208/s12248-015-9811-z. Epub 2015 Sep 3. PubMed PMID: 26335307; PubMed Central PMCID: PMC4627456.
32. Khan S, Chauhan N, Yallapu MM, Ebeling MC, Balakrishna S, Ellis RT, Thompson PA, Balabathula P, Behrman SW, Zafar N, Singh MM, Halaweish FT, **Jaggi M**, Chauhan SC. Nanoparticle formulation of ormeloxifene for pancreatic cancer. *Biomaterials*. 2015;53:731-43. doi: 10.1016/j.biomaterials.2015.02.082. Epub 2015 Mar 26. PubMed PMID: 25890768; PubMed Central PMCID: PMC4405677.
33. Khan S, Ebeling MC, Chauhan N, Thompson PA, Gara R, Ganju A, Yallapu MM, Behrman SW, Zhao H, Zafar N, Singh MM, **Jaggi M**, Chauhan SC. Ormeloxifene Suppresses Desmoplasia and Enhances Sensitivity of Gemcitabine in Pancreatic Cancer. *Can Res*, 2015, Apr 3. pii: canres.2397.2014. [Epub ahead of print]. PMID: 25840985.
34. Khan S, Chauhan N, Yallapu MM, Ebeling MC, Balakrishna S, Ellis RT, Thompson PA, Balabathula P, Behrman SW, Zafar N, Singh MM, Halaweish FT, **Jaggi M**, Chauhan SC. Nanoparticle formulation of ormeloxifene for pancreatic cancer. *Biomaterials*, 2015, 53:731-743
35. Yallapu MM, Chauhan N, Othman SF, Khalilzad-Sharghi V, Ebeling MC, Khan S, **Jaggi M**, Chauhan SC. Implications of protein corona on physico-chemical and biological properties of magnetic nanoparticles. *Biomaterials*. 2015, 46:1-12. PubMed PMID: 25678111.
36. Khan S., Ebeling MC., Zaman MS., Sikander M., Yallapu MM., Chauhan N., Yacoubian AM., Behrman SW., Zafar N., Kumar D., Thompson PA., **Jaggi M**. and Chauhan SC. MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer. *Oncotarget*. 5(17):7599-7609
37. Maher DM, Khan S, Nordquist J, Ebeling MC, Bauer NA, Kopel L, Singh MM, Halaweish F, Bell MC, **Jaggi M**, Chauhan SC. Ormeloxifene efficiently inhibits ovarian cancer growth. *Cancer Letters*. 2014 Oct 9. pii: S0304-3835(14)00597-7. doi: 10.1016/j.canlet.2014.10.009. [Epub ahead of print] PubMed PMID: 25306892.
38. Ganju A, Yallapu MM., Khan S, Behrman SW., Chauhan SC and **Jaggi M***. Nanoways to Overcome Docetaxel Resistance in Prostate Cancer, *Drug Resistance Updates* (Impact factor 11), 2014 Apr;17(1-2):13-23. doi: 10.1016/j.drug.2014.04.001. Epub 2014 Apr 5. PMID: 24853766.
39. Gara RK, Kumari S, Ganju A, Yallapu MM, **Jaggi M**, Chauhan SC. Slit/Robo pathway: a promising therapeutic target for cancer. *Drug Discov Today*. 2014 Sep 19. pii: S1359-

6446(14)00357-2. doi: 10.1016/j.drudis.2014.09.008. [Epub ahead of print] Review. PubMed PMID: 25245168.

40. Sundram V, Ganju A, Hughes JE, Khan S, Chauhan SC, **Jaggi M**. Protein kinase D1 attenuates tumorigenesis in colon cancer by modulating β -catenin/T cell factor activity. *Oncotarget*. 2014;5(16):6867-84. PubMed PMID: 25149539.
41. Yallapu MM, Katti KS, Katti DR, Mishra SR, Khan S, **Jaggi M**, Chauhan SC. The Roles of Cellular Nanomechanics in Cancer. *Med Res Rev*. 2014. doi:10.1002/med.21329. [Epub ahead of print] PubMed PMID: 25137233
42. Gupta BK., Maher DM., Ebeling MC., Stephenson PD., Puumala SE., Koch MRD., Aburatani H., **Jaggi M** and Chauhan SC. Functions and regulation of MUC13 mucin in colon cancer cells. *Journal of Gastroenterology* (In Press). PMID: 24097071
43. Khan S., Ansarullah., Kumar D., **Jaggi M**. and Chauhan SC. Targeting microRNAs in pancreatic cancer: microplayers in the big game. *Cancer Research*, 2013; 15;73(22):6541-7. PMID: 24204026
44. Yallapu MM, Ebeling MC, **Jaggi M**, Chauhan SC. Plasma proteins interaction with curcumin nanoparticles: implications in cancer therapeutics. 2013;14(4):504-15 PMID: 23566382
45. Gara RK, Sundram V., Chauhan SC. and **Jaggi M**. Anti-cancer potential of a novel SERM ormeloxifene. *Current Medicinal Chemistry* 2013; 20(33):4177-84. PMID 23895678
46. Yallapu MM., Ebeling MC., Khan S., Sundram V., Chauhan N., Gupta BK., Puumala SE., **Jaggi M** and Chauhan SC. Novel curcumin loaded magnetic nanoparticles for pancreatic cancer treatment. *Molecular Cancer Therapeutics* 2013; 8: 1471-80. PMID 23704793
47. Yallapu MM., **Jaggi M**, and Chauhan SC. Curcumin Nanomedicine: A Road to cancer therapeutics. *Current Pharmaceuticals Designs* 2013 19(11):1994-2010. PMID: 23116309
48. Zaman MS., Maher DM., Khan S., **Jaggi M**. and Chauhan SC. Current status and implications of microRNAs in ovarian cancer diagnosis and therapy. *J Ovarian Res*. 2012 Dec 13;5(1):44.
49. Gupta BK, Maher DM, Ebeling MC, Sundram V, Koch MD, Lynch DW, Bohlmeyer T, Watanabe A, Aburatani H, Puumala SE, **Jaggi M**, Chauhan SC. Increased expression and aberrant localization of mucin 13 in metastatic colon cancer. *J Histochem Cytochem*. 2012 Nov;60(11):822-31 PMID: 22914648

50. Yallapu MM., Othman SF., Curtis ET., Nichole AB., Chauhan N., Kumar D., **Jaggi M** and Chauhan SC. Curcumin loaded magnetic nanoparticles for breast cancer therapeutics and imaging applications. *International Journal of Nanotechnology* 2012;7:1761-79
51. Sundram V., Chauhan SC. and **Jaggi M**. Curcumin attenuates β -catenin signaling in prostate cancer cells through activation of protein kinase D1. *PLoS One* 2012;7(4):e35368
52. Chauhan SC., Ebeling MC., Maher DM., Watanabe A., Koch MD., Aburatani H., Lio Y. and **Jaggi M**. MUC13 mucin augments pancreatic tumorigenesis. *Molecular Cancer Therapeutics* 2012 11(1):24-33 (*Selected for cover page*)
53. Yallapu MM., Ebeling MC., Chauhan N., **Jaggi M**. and Chauhan SC. Interaction of curcumin nanoformulations with human plasma proteins and erythrocytes. *International Journal of Nanotechnology* 2011;6:2779-90
54. Yallapu MM., Doberphool M., Maher DM., **Jaggi M**. and Chauhan SC. Design of Curcumin loaded Cellulose Nanoparticles for Prostate Cancer. *Current Drug Metabolism* 2012;13(1):120-8
55. Yallapu MM., **Jaggi M**, and Chauhan SC. Curcumin Nanoformulations: A Future Nanomedicine for Cancer. *Drug Discovery Today* 2012 Jan;17(1-2):71-80.
56. Sundram V., Chauhan SC. and **Jaggi M**. Emerging roles of protein kinase D1 in cancer. *Molecular Cancer Research* 2011 9(8):985-96.
57. Yallapu MM., **Jaggi M**, and Chauhan SC. Design and engineering of nanogels for cancer treatment. *Drug Discovery Today* 2011; 16(9-10):457-63
58. Maher DM., Gupta B.K., Nagata S., **Jaggi M**, and Chauhan SC. MUC13: structure, function and role in cancer pathogenesis. *Molecular Cancer Research* 2011 May;9(5):531-7.
59. Maher DM., Bell MC., O'Donnell E., Gupta B.K., **Jaggi M**, and Chauhan SC. Curcumin suppresses Human Papillomavirus oncoproteins, restores expression of p53, pRb and PTPN13 proteins and inhibits benzo[a]pyrene induced upregulation of HPV E7. *Molecular Carcinogenesis* 2011;50(1):47-57.
60. Yallapu MM., Othman SF., Curtis ET., Gupta B., **Jaggi M** and Chauhan SC. Multi-functional Magnetic Nanoparticles for Magnetic Resonance Imaging and Cancer Therapy. *Biomaterials* 2011 Mar;32(7):1890-905
61. Yallapu MM., **Jaggi M**, and Chauhan SC. Scope of nanotechnology in ovarian cancer therapeutics. *Journal of Ovarian Research* 2010, Aug 6;3:19

62. Yallapu MM., Gupta B., **Jaggi M** and Chauhan SC. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. *Journal of Colloid & Interface Science* 2010,1;351(1):19-29 (**selected for cover illustration**) Yallapu MM., **Jaggi M**, and Chauhan SC. β -Cyclodextrin-Curcumin Self-assembly Enhances Curcumin Delivery in Prostate Cancer Cells. *Colloids and Surfaces B: Biointerfaces*, 2010 Aug 1;79(1):113-25
63. Yallapu MM., **Jaggi M**, and Chauhan SC. Poly(β -cyclodextrin)-Curcumin Self-assembly : A Novel Approach to Improve Curcumin Delivery and its Therapeutic Efficacy in Prostate Cancer Cells. *Macromolecular Bioscience* 2010, 8;10(10):1141-51 (**selected for cover illustration**)
64. Yallapu MM., Maher DM., Sundram V., **Jaggi M**, and Chauhan SC. Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. *Journal of Ovarian Research* 2010 Apr 29;3:11
65. Chauhan SC., Kumar D. and **Jaggi M**. Mucins in ovarian cancer diagnosis and therapy. *Journal of Ovarian Research* 2009 Dec 24;2(1):21)
66. **Jaggi M**#, Du C#, Zhang C. and Balaji KC. Protein kinase D1 (PKD1) mediated phosphorylation and subcellular localization of β -catenin. *Cancer Research* 2009;69(3) (# equal contribution)
67. **Jaggi M***, Chauhan SC., Du C. and Balaji KC. Bryostatins modulates β -catenin subcellular localization and transcription activity through protein kinase D1 activation. *Molecular Cancer Therapeutics* 2008;7(9):2703-12 (**Cover illustration**)
68. Paul M., **Jaggi M**., Viqar S., Chauhan SC., Hassan S., Biswas H., Balaji K.C. Protein kinase D1 (PKD1) influences androgen receptor (AR) function in prostate cancer cells. *Biochemical and Biophysical Research Communications* 2008 Sep 373:618-23
69. Jaggi BK., Chauhan SC. and **Jaggi M***. Effect of curcumin on signaling pathways in cancer. *Proceedings of South Dakota Academy of Science (PSDAS)* 2007; 86:283-293
9
70. **Jaggi M***, Du C., Zhang W., and Balaji K. C. Protein Kinase D1: A Protein of Emerging Translational Interest. *Front Biosci.* 2007 May 1;12: 3757-67.
71. S C Chauhan., N.Vinayek., K. Dunham., Y. Lio., Koch MD. and **Jaggi M**. Analysis for MUC1, MUC16 and TAG-72 expression in ovarian cancer: Antigens of multi-targeted antibody guided therapy. *Journal of Histochemistry and Cytochemistry*, .2007 Aug;55(8):867-75.
72. Du C, **Jaggi M**, Zhang W, Balaji KC. PKD1 (Protein Kinase D1). *Atlas Genet Cytogenet Oncol Haematol*. January 2006. URL: <http://AtlasGeneticsOncology.org/Genes/PRKCMID41860ch14q11.html>

73. Smith D. J., **Jaggi M.**, Zhang W., Galich A. N., Sterrett S. P., Smith L. M., and Balaji K. C., Methallothioneins and Resistance to Cisplatin and Radiation in Prostate Cancer. *Urology*. 2006 Jun;67 (6):1341-7.
74. **Jaggi M***, Nazemi T., Baker J. J., Galich A. N., Smith L. M., and Balaji K. C. N-cadherin Switching Occurs in High Gleason Grade Prostate Cancer. *Prostate*, 2006; 66(2): 193-199.
75. **Jaggi M***, Johansson S. L., Smith L. M., Baker J. J., Galich A. N., Balaji K. C. Aberrant Expression of E-Cadherin and Beta-Catenin in Human Prostate Cancer. *Urological Oncology*, 2005, 23(6): 402-406
76. Lewis T., Milam T., Rao P., **Jaggi M.**, Smith D., Hemstreet G., Balaji K. C., Tissue Transglutaminase Interacts with AKAP 13 in Prostate Cancer. *Urological Oncology*, 2005, 23(6): 407-412.
77. **Jaggi M.**, Rao P. S., Smith D. J., Wheelock M. J. and Johnson K.R, Hemstreet G. P. and Balaji K. C. E-cadherin Phosphorylation by PKD1/PKC mu is Associated with Altered Cellular Aggregation and Motility in Prostate Cancer. *Cancer Research*, 2005 65(2): 483-492.
78. Rao P. S., **Jaggi M.**, Smith D. J., Hemstreet G. P. and Balaji K. C. Metallothionein 2A interacts with the kinase domain of PKCmu in prostate cancer. *Biochem Biophys Res Commun*. 2003, 310(3): 1032-1038.
79. **Jaggi M.**, Rao P. S., Smith D. J., Hemstreet G. P. and Balaji K. C. Protein kinase C mu is down-regulated in androgen-independent prostate cancer. *Biochemical and Biophysical Research Communications*, 2003; 307(2): 254-260.
80. **Jaggi M.**, Wheelock M. J and Johnson K.R. Differential displacement of classical cadherins by VE cadherin. *Cell Communication and Adhesion*, 2002, 9(2): 103-115.
81. **Jaggi M.**, Farheen S., and Mehrotra P.K. Use of differentiating human trophoblast in *in vitro* assay. *In Vitro Cell Dev Biol Anim.*, 1999, 35(8): 427-430.
82. **Jaggi M.**, Mehrotra P. K., Maitra S. C., Agarwal S. L., and Das K. Ultrastructure of intermediate trophoblast cells during morphogenesis of syncytiotrophoblast in human early pregnancy. *Early Pregnancy: Biology and Medicine*, 1997, 3: 1-6.
83. **Jaggi M.**, Mehrotra P. K., Maitra S. C., Agarwal S. L., Das K., and Kamboj V. P.. Ultrastructure of cellular components of human trophoblasts during early pregnancy. *Reprod. Fertil. Dev.*, 1995, 7: 1529-1546.
84. **Jaggi M.**, Mehrotra P. K., Maitra S. C., Agarwal S. L., and Das K.. Role of intermediate cells in differentiation of cyto to Syncytiotrophoblast during first trimester of human

pregnancy. Proc. I.C.M.R. Young Scientist Symp on "*Frontiers in Reproductive Biology*", 1995, Bombay, February 10-11.

OTHER PUBLICATIONS:

Sanford Health, Sioux Falls, Mach, 17, 2009, "*Sanford Researcher Published in Top Cancer Research Journal*"

7. YWCA, Sioux Falls, April 2, 2009, Tribute to women "*Science and Technology*

8. Argus Leader, Friday, April 3, 2009, "*Tribute to Women*"

9. Interviewed in the, May, 20, 2009, Q&A of the Sioux Falls Business Journal, "*Jaggi's cancer research help put pieces together to save lives*"

10. Sioux Falls Woman, June/July 2009, Vol 7, Issue 4, A tribute to Women YWCA, of Sioux Falls Honors 10 Inspirational Women

RECENT PRESENTATIONS:

1. 1449 / 19 - Aberrant expression of protein kinase D1 influences metabolic reconditioning in pancreatic cancer, S. Kumari, S. Khan, M. M. Yallapu, S. C. Chauhan, M. Jaggi; April 16, 2018, 8:00 AM - 12:00 PM, AACR 2018, Chicago, Illinois.
2. 198 / 28 - MUC13 promotes pancreatic tumor-stromal interactions by influencing tumor microenvironment, S. S. Khan, K. Doxtater, S. Kumari, S. Setua, M. Sikander, S. Malik, M. M. Yallapu, S. W. Behrman, S. C. Chauhan, M. Jaggi, April 15, 2018, 1:00 PM - 5:00 PM, AACR 2018, Chicago, Illinois.
3. 679 / 2 - ABI-231: A novel small molecule suppresses tumor growth and metastatic phenotypes of cervical cancer cells via targeting HPV E6 and E7, V. K. Kashyap, B. B. Hafeez, Q. Wang, N. Chauhan, P. K. B. Nagesh, N. Dan, s. kumari, S. Malik, S. Setua, A. Ganju, M. M. Yallapu, D. D. Miller, W. Li, M. Jaggi, S. C. Chauhan, April 15, 2018, 1:00 PM - 5:00 PM, AACR 2018, Chicago, Illinois.
4. LB-011 / 11 - Novel nano-formulation of paclitaxel for pancreatic cancer therapy, B. B. Hafeez, A. E. Massey, V. K. Kashyap, M. Sikander, A. Shetty, M. Chaib, H. Mandil, M. Yallapu, M. Jaggi, S. C. Chauhan, April 15, 2018, 1:00 PM - 5:00 PM, AACR 2018, Chicago, Illinois.
5. 2110 / 25 - Therapeutic intervention for pancreatic cancer using autologous exosomes, S. Setua, S. Khan, M. Yallapu, S. Kumari, M. Jaggi, S. C. Chauhan; April 16, 2018, 1:00 PM - 5:00 PM, Chicago, Illinois.
6. 4657 / 20 - Docetaxel nanoformulation reverts drug resistance in prostate cancer, P. B. Nagesh, P. Chowdhury, E. Hatami, V. K. Kashyap, B. B. Hafeez, S. Khan, S. C. Chauhan, M. Jaggi, M. Yallapu, April 17, 2018, 1:00 PM - 5:00 PM, AACR 2018, Chicago, Illinois.
7. LB-400 / 28 - Tannic acid induces prostate cancer cell death via unfolded protein response (UPR) and modulation of CHOP, E. Hatami, P. Bhusetty Nagesh, P. Chowdhury, V. K. Kashyap, S. Khan, B. Hafeez, M. Jaggi, S. C. Chauhan, M. Yallapu; April 18, 2018, 8:00 AM - 12:00 PM, AACR 2018, Chicago, Illinois.
8. 5777 / 3 - Ormeloxifene augments the therapeutic response of enzalutamide via targeting

- androgen receptor splice variant 7, B. B. Hafeez, A. E. Massey, V. K. Kashyap, M. Sikander, A. Shetty, M. Chaib, H. Mandil, S. Malik, M. M. Yallapu, M. Jaggi, S. C. Chauhan; April 18, 2018, 8:00 AM - 12:00 PM AACR 2018, Chicago, Illinois.
9. 2934 / 14 - Cucurbitacin D enhances the therapeutic efficacy of docetaxel via targeting cancer stem cells and miR-145, M. Sikander, S. Malik, B. B. Hafeez, H. Mandil, F. T. Halaweish, M. Jaggi, S. C. Chauhan; April 16, 2018, 1:00 PM - 5:00 PM, AACR 2018, Chicago, Illinois.
 10. 5178 / 10 - MUC13 is a novel molecular signature, for early detection and metastatic colorectal cancer, M. K. Tripathi¹, C. Zacheaus, K. Doxtater, Z. Stiles, F. Keramatnia, N. Zafar, M. Amin, M. Jaggi, S. Chauhan, April 18, 2018, 8:00 AM - 12:00 PM, AACR 2018, Chicago, Illinois.
 11. 5138 / 19 - Comparative profiling for bacterial inhabitation in pancreatic ductal adenocarcinoma and matched adjacent normal tissues, S. S. Khan, P. Banerjee, S. Setua, D. Higgins, S. Kedia, Y. Jiang, M. Jaggi, S. Chauhan, April 18, 2018, 8:00 AM - 12:00 PM, AACR 2018, Chicago, Illinois.
 12. M4065 - Docetaxel Loaded Magnetic Nanoparticles for Overcoming Drug Resistance in Prostate Cancer, Pallabita Chowdhury, Prashanth Kumar Nagesh, Elham Hatami, Sheema Khan, Subhash Chauhan, Meena Jaggi, Murali Yallapu, November 13 – Monday Time: 12:00 pm - 01:00 pm, AAPS 2017, San Diego.
 13. W1020 - Physico-Chemical and Biological Interactions of Protein Corona of Human Lung Fluid with Tannic Acid Nanoformulation, Elham Hatami, Pallabita Chowdhury, Prashanth Bhusetty, Subhash Chauhan, Meena Jaggi, Murali Yallapu, 9:00 AM–10:00 AM Nov 15, 2017, AAPS 2017, San Diego.
 14. M7068 - Self- Targeting Nanoparticles as a Potential Therapeutic Model for Targeting Cancer, Pallabita Chowdhury, Elham Hatami, Prashanth Kumar Nagesh, Sheema Khan, Subhash Chauhan, Meena Jaggi, Murali Yallapu, 3:00 PM–4:00 PM Nov 13, 2017, AAPS 2017, San Diego.
 15. M5029 - Mir-145 Mediated TRAIL Sensitization In Pancreatic Cancer: Novel Combined Treatment Strategy, Saini Setua, Sheema Khan, Murali Yallapu, Stephen Behrman, Meena Jaggi, Subhash Chauhan, Poster Forum 2 - Monday - 01:00 pm, AAPS 2017, San Diego.
 16. M7015 - Therapeutic Perspectives of Tannic Acid in Inducing ER Stress Mediated Unfolded Protein Response (UPR) in Prostate Cancer Cell Death, Prashanth Kumar Bhusetty Nagesh, Pallabita Chowdhury, Vivek Kumar Kashyap, Elham Hatami, Sheema Khan, Bilal Hafeez, Meena Jaggi, Subhash Chauhan, Murali Yallapu, Poster Forum 2 - Monday - 03:00 pm, AAPS 2017, San Diego.
 17. W1128 - ABI-231: A novel microtubule inhibitor suppresses tumor growth and metastatic phenotypes of cervical cancer cells via targeting HPV E6 and E7, Vivek Kashyap, Bilal Hafeez, Qinghai Wang, Neeraj Chauhan, Prashanth K B Nagesh, Nirnoy Dan, Shabnam Malik, Saini Setua, Aditya Ganju, Murali Yallapu, Duane Miller, Wei Li, Meena Jaggi, Subhash Chauhan, Poster Forum 6 - Wednesday - 09:00 am, AAPS 2017, San Diego.
 18. Partial wave spectroscopy based nanoscale structural disorder analysis for cancer diagnosis and treatment, Almadadi, Huda; Sahay, Peeyush; Nagesh, Prashanth K. B.; Yallapu, Murali M.; Jaggi, Meena; Chauhan, Subhash C.; Pradhan, Prabhakar, APS March Meeting 2017, abstract id. Y6.008
 19. #37 - MUC13 PEPTIDE MODULATES TME OF PANCREATIC CANCER BY

- INDUCTION OF TAMs AND ACTIVATION OF CAFs: Mehdi Chaib, Advait Shetty, Andrew Massey, Sonam Kumari, Vivek Kashyab, Manish Tripathi, Bilal Hafeez, Meena Jaggi, Subhash C. Chauhan, April 20th, 2018, 1:00-3:00 PM, Graduate Research Day, University of Tennessee Health Science Center, Memphis, TN, USA.
20. #40 - DOCETAXEL LOADED MAGNETIC NANOPARTICLES FOR OVERCOMING DRUG RESISTANCE IN PROSTATE CANCER: Pallabita Chowdhury, Prashanth K.B. Nagesh, Elham Hatami, Sheema Khan, Subhash C. Chauhan, Meena Jaggi, Murali M. Yallapu April 20th, 2018, 1:00-3:00 PM, Graduate Research Day, University of Tennessee Health Science Center, Memphis, TN, USA.
 21. #39 - TARGETED DRUG DELIVERY USING NOVEL ANTI_MUC12 CONJUGATED NANOPARTICLES FOR PANCREATIC CANCER: Nirnoy Dan, Saini Setua, Sheema Khan, Murali M. Yallapu, Meena Jaggi, Subhash C. Chauhan April 20th, 2018, 1:00-3:00 PM, Graduate Research Day, University of Tennessee Health Science Center, Memphis, TN, USA.
 22. #34 - TANNIC ACID INDUCES ENDOPLASMIC RETICULUM STRESS-MEDIATED APOPTOSIS IN PROSTATE CANCER: Elham Hatami, Prashanth K.B. Nagesh, Pallabita Chowdhury, Vivek Kashyab, Sheema Khan, Bilal Hafeez, Subhash C. Chauhan, Meena Jaggi, Murali M. Yallapu, April 20th, 2018, 1:00-3:00 PM, Graduate Research Day, University of Tennessee Health Science Center, Memphis, TN, USA.
 23. #36 - ABERRANT EXPRESSION OF PROTEIN KINASE D1 INFLUENCES METABOLIC RECONDITIONING IN PANCREATIC CANCER: Sonam Kumari, Sheema Khan, Murali M. Yallapu, Subhash C. Chauhan, Meena Jaggi April 20th, 2018, 1:00-3:00 PM, Graduate Research Day, University of Tennessee Health Science Center, Memphis, TN, USA.
 24. #32 - ASSESSMENT OF PHYSICAL CHARACTERISTICS OF CANCER CELLS AND NANOPARTICLES BY ATOMIC FORCE MICROSCOPY: Andrew Massey, April 20th, 2018, 1:00-3:00 PM, Graduate Research Day, Graduate Research Day, University of Tennessee Health Science Center, Memphis, TN, USA.
 25. #35 - TARGETING MUC12 TO IMPROVE SURVIVAL IN PATIENTS WHO SMOKE AND DRINK: Kamalika Samanta, Sheema Khan, Saini Setua, Sonam Kumari, Nirnoy Dan, Kyle Doxtater, Pragathi Reddy Gunnam, Murali M. Yallapu, Meena Jaggi, Subhash C. Chauhan, April 20th, 2018, 1:00-3:00 PM, Graduate Research Day, University of Tennessee Health Science Center, Memphis, TN, USA.
 26. #43 - THERAPEUTIC INTERVENTION FOR PANCREATIC CANCER USING AUTOLOGOUS EXOSOMES: Saini Setua, Sheema Khan, Andrew Massey, Murali M. Yallapu, Meena Jaggi, Subhash C. Chauhan, April 20th, 2018, 1:00-3:00 PM, Graduate Research Day, University of Tennessee Health Science Center, Memphis, TN, USA.
 27. Aditya Ganju, Bilal B. Hafeez, Mohammad Sikander, Vivek K Kashyap, Murali M. Yallapu, Subhash C. Chauhan, **Meena Jaggi**. Ormeloxifene suppress the growth of prostate tumor via inhibition of β -catenin induced AR signaling. *AACR Annual Meeting 2017*, April 1 – 5, 2017, Washington, D.C.
 28. Sheema Khan, Stephen W Behrman, Nadeem Zafar, **Meena Jaggi**, Subhash C Chauhan. MUC13- An early diagnostic marker for pancreatic ductal adenocarcinoma. SSAT, 57th

- Annual Meeting May 21-24, 2016, San Diego California. San Diego California. 50th Annual Pancreas Club Meeting May 20-21, 2016, San Diego California.
29. Saini Setua, MS, Sheema Khan, Murali M Yallapu, Stephen W Behrman, **Meena Jaggi**, Subhash C Chauhan. Restitution of tumor suppressor mir-145 using magnetic nanoparticles inhibits pancreatic cancer. *Invited Oral Talk; 50th Annual Pancreas Club Meeting May 20-21, 2016, San Diego California. SSAT, 57th Annual Meeting May 21-24, 2016, San Diego California.*
 30. Stephen W Behrman, Sheema Khan, Nadeem Zafar, **Meena Jaggi**, Subhash C Chauhan. MUC13 interaction with receptor tyrosine kinase HER2 drives pancreatic ductal adenocarcinoma progression. *SSAT, 57th Annual Meeting May 21-24, 2016, San Diego California. 50th Annual Pancreas Club Meeting May 20-21, 2016, San Diego California.*
 31. Saini Setua, Sheema Khan, Murali M. Yallapu, Stephen W. Behrman, Nadeem Zafar, Meena Jaggi, Subhash C. Chauhan. Targeting MUC13 to Overcome the Survival Mechanisms for Improved Response to Chemotherapy. *AACR Annual Meeting 2017*, April 1 – 5, 2017, Washington, D.C.
 32. Saini Setua, Sheema Khan, Murali M. Yallapu, Mohammed Sikander, **Meena Jaggi**, Subhash C. Chauhan. Development of a microRNA-145 magnetic nanoformulation for pancreatic cancer therapy. *AAPS Annual Meeting 2016*, November 13-17, 2016, Colorado, Denver.
 33. Saini Setua, Sheema Khan, Murali M. Yallapu, **Meena Jaggi**, Subhash C. Chauhan. MicroRNA-145 overcomes chemo-resistance in pancreatic cancer leading to combined treatment interventions. *Graduate research day, 2016*. University of Tennessee Health Science Center, USA.
 34. Saini Setua, Sheema Khan, Murali M. Yallapu, **Meena Jaggi**, Subhash C. Chauhan. MUC13 is involved in TRAIL resistance in pancreatic cancer. *Graduate research day, 2017*. University of Tennessee Health Science Center, USA.
 35. Saini Setua, Sheema Khan, Kyle Doxtater, Murali M. Yallapu, **Meena Jaggi**, and Subhash C. Chauhan. miR-145: Revival of a Dragon in Pancreatic Cancer. *Journal of Nature and Science (JNSCI)*, 3(3):e332, 2017
 36. Saini Setua, Saini Setua, **Meena Jaggi**, Murali M. Yallapu, Subhash C. Chauhan. Multifunctional magnetic nanoparticles for cancer treatment. *Nanotechnologies in Preventive and Regenerative Medicine*. Elsevier Book chapter.[Epub ahead of print].
 37. Bilal B Hafeez, Vivek K Kashyap, Vijayakumar N Boya, Aditya Ganju, Mohammad Sikander, Murali M Yallapu, **Meena Jaggi**, Subhash C Chauhan. Novel nanoparticle formulation of Plumbagin for pancreatic cancer treatment. *AAPS Annual Meeting 2016*, November 13-17, 2016, Colorado, Denver.
 38. Mohammed Sikander¹, Bilal Bin Hafeez¹, Shabnam Malik¹, Aditya Ganju¹, Fathi T. Halaweish², Murali Mohan Yallapu¹, Subhash C. Chauhan¹, Meena Jaggi. Cucurbitacin D inhibits prostate tumor growth via targeting glucose metabolism. . *AACR Annual Meeting 2017*, April 1 – 5, 2017, Washington, D.C.
 39. Nirnoy Dan, Saini Setua, Sheema Khan, Murali M. Yallapu, **Meena Jaggi**, Subhash C. Chauhan Targeted drug delivery using a novel anti-MUC13 conjugated nanoparticles for pancreatic cancer. *Graduate research day, 2017*. University of Tennessee Health Science Center, USA.

40. Kyle Doxtater, Sheema Khan, Sonam Kumari, Saini Setua, Mohammad Sikander, Shabnam Malik, Murali M. Yallapu, Subhash C. Chauhan, **Meena Jaggi**. MUC13 promotes pancreatic tumor-stromal interactions by influencing tumor microenvironment. *Graduate research day, 2017*. University of Tennessee Health Science Center, USA.
41. Sonam Kumari, Sheema Khan, Subash C. Gupta, Vivek K. Kashyap Murali M. Yallapu, Subhash C. Chauhan, **Meena Jaggi**. MUC13 induced NF κ B activation regulates metabolic reprogramming by promoting crosstalk with GLUT-1 receptor. *AACR Annual Meeting 2017*, April 1 – 5, 2017, Washington, D.C.
42. Sonam Kumari, Sheema Khan, Subash C. Gupta, Vivek K. Kashyap Murali M. Yallapu, Subhash C. Chauhan, **Meena Jaggi**. MUC13 induced NF κ B activation regulates metabolic reprogramming by promoting crosstalk with GLUT-1. Graduate research day, 2017. University of Tennessee Health Science Center, USA.
43. Vivek K Kashyap, Bilal B. Hafeez., Qinghui Wang, Saini Setua, Aditya Ganju, Murali M. Yallapu, Duane D. Miller, Wei Li , **Meena Jaggi**, Subhash C. Chauhan. Attenuation of pancreatic tumor growth by a small molecule tubulin inhibitor. *AACR Annual Meeting 2017*, April 1 – 5, 2017, Washington, D.C.
44. V. K. Kashyap, Q. Wang, B. B. Hafeez, A. K. Ganju, M. M. Yallapu, D. Miller, L. Wei, **M. Jaggi**, S. Chauhan. ABI-231 Inhibits the Growth of Pancreatic Cancer Cells In Vitro and In Vivo via Targeting BetaTubulin. . *AAPS Annual Meeting 2016*, November 13-17, 2016, Colorado, Denver.
45. Aditya Ganju, Bilal B Hafeez, Fathi Halaweish, Wei Li, Murali Mohan Yallapu, Subhash Chauhan, **Meena Jaggi**. Pharmacological Activation of PKD1 by Ormeloxifene Induces Docetaxel Sensitivity in Prostate Cancer Cells. *9th World Drug Delivery Summit pre-conference 25 April, 2016* University of Tennessee Health Science Center, USA
46. Bilal B Hafeez, Vivek K Kashyap, Aditya Ganju, Vijayakumar N Boya, Mohammed Sikander, Murali M Yallapu, **Meena Jaggi** and Subhash C Chauhan. Nanoparticle formulation of Plumbagin: A novel modality for pancreatic cancer treatment. *9th World Drug Delivery Summit pre-conference 25 April, 2016* University of Tennessee Health Science Center, USA
47. M Murali M. Yallapu, **Meena Jaggi**, Subhash Chauhan. Magnetic Nanoparticles: Design to Therapeutic Applications, *9th World Drug Delivery Summit pre-conference 25 April, 2016* University of Tennessee Health Science Center, USA
48. Peeyush Sahay, Aditya Ganju, Hemendra Ghimire, Huda Almabadi, Murali Yallapu, Omar Skalli, **Meena Jaggi**, Subhash Chauhan, and Prabhakar Pradhan. A novel method for quantifying intracellular structural alterations using confocal fluorescence imaging. *9th World Drug Delivery Summit pre-conference 25 April, 2016* University of Tennessee Health Science Center, USA
49. Neeraj Chauhan, Murali Mohan Yallapu, **Meena Jaggi** and Subhash C. Chauhan. Ormeloxifene loaded PLGA nanoparticles: A novel nano-approach for cervical cancer therapeutics. *9th World Drug Delivery Summit pre-conference 25 April, 2016* University of Tennessee Health Science Center, USA

50. Saini Setua, Sheema Khan, Murali M Yallapu, **Meena Jaggi** and Subhash C Chauhan. MIR-145 mediated chemo-sensitization in pancreatic cancer: A novel strategy for combined treatment intervention. *9th World Drug Delivery Summit pre-conference* 25 April, 2016 University of Tennessee Health Science Center, USA
51. Sheema Khan, Murali M Yallapu, Saini Setua, Sonam Kumari, Aditya Ganju, Swathi Balakrishna, Stephen W Behrman, Nadeem Zafar, **Meena Jaggi** and Subhash C Chauhan. Targeting Tumor Microenvironment in Pancreatic Cancer Using a Novel Drug Delivery Approach. *9th World Drug Delivery Summit pre-conference* 25 April, 2016 University of Tennessee Health Science Center, USA
52. Vivek Kr Kashyap, Qinghui Wang, Bilal B Hafeez, Aditya Ganju, Sonam Kumari, Murali M Yallapu, Duane D Miller, Wei Li, **Meena Jaggi** and Subhash C Chauhan. ABI-231 inhibits the growth of pancreatic cancer cells in vitro and in vivo via targeting beta-tubulin. *9th World Drug Delivery Summit pre-conference* 25 April, 2016 University of Tennessee Health Science Center, USA
53. Sonam Kumari, Sheema Khan, Subhash Chauhan, **Meena Jaggi**. MUC13 regulates glucose metabolism in pancreatic cancer. *9th World Drug Delivery Summit pre-conference* 25 April, 2016 University of Tennessee Health Science Center, USA
54. Prashanth K.B. Nagesh, Nia R. Johnson, Vijaya K.N. Boya, Pallabita Chowdhury, Shadi F. Othman, Vahid Khalilzad-Sharghi, Bilal B. Hafeez, Aditya Ganju, Sheema Khan, Stephen W. Behrman, Nadeem Zafar, Subhash C. Chauhan, **Meena Jaggi** and Murali M. Yallapu. Therapeutic implication of PSMA antibody functionalized docetaxel encapsulated iron oxide nanoparticles. *9th World Drug Delivery Summit pre-conference* 25 April, 2016 University of Tennessee Health Science Center, USA
55. Mohammed Sikander, Bilal Bin Hafeez, Shabnam Malik, Fathi T Halaweish, Murali M Yallapu, Meena Jaggi and Subhash C Chauhan. Cuc D: A novel analogue of cucurbitacin inhibits cervical cancer cell growth in in vitro and xenograft mouse model. *9th World Drug Delivery Summit pre-conference* 25 April, 2016 University of Tennessee Health Science Center, USA
56. Saini Setua, Sheema Khan, Murali M Yallapu, Mohammed Sikander, Stephen W Behrman, **Meena Jaggi** and Subhash C Chauhan. Restitution of tumor suppressor mir-145 using magnetic nanoformulation for pancreatic cancer therapy. *9th World Drug Delivery Summit pre-conference* 25 April, 2016 University of Tennessee Health Science Center, USA
57. Shabnam Malik, Mohammed Sikander, Bilal Bin Hafeez, Aditya Ganju, Fathi T. Halaweish, Subhash C. Chauhan, and Meena Jaggi. Therapeutic Potential of Bromo-Ormeloxifene in Cervical Cancer. *9th World Drug Delivery Summit pre-conference* 25 April, 2016 University of Tennessee Health Science Center, USA
58. Aditya Ganju, Bilal Bin Hafeez, Fathi Halaweish, Wei Li, Man Mohan Singh, Murali Mohan Yallapu, Subhash Chauhan, **Meena Jaggi**. Ormeloxifene, a novel pharmacological activator of PKD1 enhances docetaxel sensitivity in prostate cancer. Abstract Number 3862, Poster Session 19, *American Association of Cancer Research (AACR) Annual Meeting 2016 (April 16-20), New Orleans, LA.*

59. Sonam Kumari, Sheema Khan, Subhash Chauhan, **Meena Jaggi**. Role of MUC13 as non-hypoxic stimuli inducing HIF-1 α in pancreatic cancer under normoxia. Abstract Numer 51, Poster Session 2, *American Association of Cancer Research (AACR) Annual Meeting 2016 (April 16-20), New Orleans, LA*.
60. Sheema Khan, Mara C. Ebeling, Mohammad Sikander, Aditya Ganju, Murali M. Yallapu, Tomoko Ise, Satoshi Nagata, Stephen W. Behrman, Nadeem Zafar, Jim Y. Wan, Hemendra M. Ghimire, Peeyush Sahay, Prabhakar Pradhan, **Meena Jaggi**, Subhash C. Chauhan. MUC13 interaction with receptor tyrosine kinase HER2 drives pancreatic ductal adenocarcinoma progression. Abstract Number 4592, Poster Session 8, *American Association of Cancer Research (AACR) Annual Meeting 2016 (April 16-20), New Orleans, LA*.
61. Mohammed Sikander, Bilal Bin Hafeez, Fathi T. Halaweish, Murali M. Yallapu, **Meena Jaggi**, Subhash C. Chauhan. Novel cucurbitacin analogue Cuc D exhibits potent anti-cancer activity in cervical cancer. Abstract Number 3081, Poster Session 19, *American Association of Cancer Research (AACR) Annual Meeting 2016 (April 16-20), New Orleans, LA*.
62. Vivek K. Kashyap, Sheema Khan, Mohammad Sikander, Diane M. Maher, Santosh Kumar, Namita Sinha, Murali M. Yallapu, Nadeem Zafar, **Meena Jaggi**, Subhash C. Chauhan. Comorbidity factors associated with human papillomavirus infectivity: Implications in cervical cancer health disparity. Abstract Number 1745, Poster Session 35, *American Association of Cancer Research (AACR) Annual Meeting 2016 (April 16-20), New Orleans, LA*.
63. Saini Setua, Sheema Khan, Murali Mohan Yallapu, Mohammed Sikander, Stephen W. Behrman, **Meena Jaggi**, Subhash C. Chauhan. Mir-145 based magnetic nanoformulation for pancreatic cancer therapy. Abstract Number 1071, Poster Session 6, *American Association of Cancer Research (AACR) Annual Meeting 2016 (April 16-20), New Orleans, LA*.
64. Prashanth Kumar Bhusetty Nagesh, Nia Johnson, Vijaya K.N. Boya, Pallabita Chowdhury, Aditya Ganju, Bilal Hafeez, Sheema Khan, **Meena Jaggi**, Subhash C. Chauhan, Murali M. Yallapu. PSMA antibody functionalized docetaxel-loaded magnetic nanoparticles for prostate cancer therapy. Abstract Number 1312, Poster Session 19, *American Association of Cancer Research (AACR) Annual Meeting 2016 (April 16-20), New Orleans, LA*.
65. Vijayakumar N. Boya, Renn Lovett, Saini Satua, Vaibhav Gandhi, Prashanth K.B. Nagesh, **Meena Jaggi**, Subhash C. Chauhan, Murali M. Yallapu. Mucopenetrating magnetic nanoparticles for drug delivery. Abstract Number 2197, Poster Session 20, *American Association of Cancer Research (AACR) Annual Meeting 2016 (April 16-20), New Orleans, LA*.
66. Bilal B. Hafeez, Vivek K. Kashyap, Vijayakumar N. Boya, Aditya Ganju, Mohammad Sikander, Murali M. Yallapu, **Meena Jaggi**, Subhash C. Chauhan. Novel nanoparticle formulation of Plumbagin for pancreatic cancer treatment. Abstract Number 2208, Poster Session 20, *American Association of Cancer Research (AACR) Annual Meeting 2016 (April 16-20), New Orleans, LA*.
67. Aditya Ganju, Rishi Gara, Sonam Kumari, Man Mohan Singh, Subhash C. Chauhan, **Meena Jaggi**. Ormeloxifene attenuates wnt/ β -catenin signaling in colon cancer cells by modulation of PKD1 and glycolytic pathways 2072 Poster Session, [105](#) *American Association of Cancer Research (AACR) Annual Meeting 2015 (April 18-22), Philadelphia, PA*.
68. Rishi K. Gara, Sonam Kumari, Sheema Khan, Neeraj Chauhan, Aditya Ganju, Subhash C. Chauhan, **Meena Jaggi**. Protein Kinase D1 induces autophagic cell death through activation of endoplasmic reticulum stress in prostate cancer cells, 1001 Poster Session, [105](#) *American Association of Cancer Research (AACR) Annual Meeting 2015 (April 18-22), Philadelphia, PA*.
69. Mohd Saif Zaman, Neeraj Chauhan, Rishi K. Gara, Diane Maher, Sonam Kumari, Mohammed Sikander, Sheema Khan, Murali M. Yallapu, **Meena Jaggi**, Subhash C. Chauhan. Smoking

- Carcinogen (BaP) enhances tumorigenic phenotypes of cervical cancer cells by modulation of HPV oncogenes and microRNA profiles, 182 Poster Session, [105 American Association of Cancer Research \(AACR\) Annual Meeting 2015 \(April 18-22\), Philadelphia, PA.](#)
70. Sheema Khan, Murali M. Yallapu, Sonam Kumari, Aditya Ganju, Swathi Balakrishna, Stephen W. Behrman, Nadeem Zafar, **Meena Jaggi**, Subhash C. Chauhan. Attenuation of pancreatic cancer stemness and growth by a novel magnetic nanoparticle formulation, 3676 Poster Session, [105 American Association of Cancer Research \(AACR\) Annual Meeting 2015 \(April 18-22\), Philadelphia, PA.](#)
 71. Sheema Khan, Neeraj Chauhan, Murali M. Yallapu, Mara C. Ebeling, Swathi Balakrishna, Robert T. Ellis, Paul A. Thompson, Stephen W. Behrman, Nadeem Zafar, Man M. Singh, Fathi T. Halaweish, **Meena Jaggi**, Subhash C. Chauhan. Generation of a novel ormeloxifene nanoparticle formulation for pancreatic cancer treatment, 4392 Poster Session. [105 American Association of Cancer Research \(AACR\) Annual Meeting 2015 \(April 18-22\), Philadelphia, PA.](#)
 72. Mohammed Sikander, Sheema Khan, Neeraj Chauhan, Mohd Saif Zaman, Murali Mohan Yallapu, Fathi T. Halaweish, Bhavin Chauhan, Shabnam Malik, **Meena Jaggi**, Subhash C. Chauhan. Anticancer activity of novel cucurbitacin analogue in pancreatic cancer, 4468 Poster Session, [105 American Association of Cancer Research \(AACR\) Annual Meeting 2015 \(April 18-22\), Philadelphia, PA.](#)
 73. Murali M. Yallapu, Neeraj Chauhan, Sheema Khan, **Meena Jaggi**, Aditya Ganju, Diane M. Maher, Mara C. Ebeling, Subhash C. Chauhan. Novel pluronic F127-coated paclitaxel nanoparticles formulation for pancreatic cancer. 5534 Poster Session, [105 American Association of Cancer Research \(AACR\) Annual Meeting 2015 \(April 18-22\), Philadelphia, PA.](#)
 74. Zafar Nadeem, Khan Sheema, Behrman Stephen W, **Jaggi Meena** and Chauhan Subhash. Suppression of Pancreatic Ductal Carcinoma Growth and Invasion By Targeting MUC13 Mucin Through MicroRNA-145- A Tumor Heterograft Study in Mice (Abstract 2467). **2015 United States & Canadian Academy of Pathology Annual Meeting (USCAP)**, March 23-27 2015, Boston, MA.
 75. Behrman Stephen W, Zafar Nadeem, Khan Sheema, **Jaggi Meena** and **Chauhan Subhash**. Surgical management of complicated pancreatic pseudocysts following acute pancreatitis. **49th Annual Pancreas Club meeting**, May 15-16, 2015, Washington, DC.
 76. Gara RK, Kumari S, Ganju A, Yallapu MM, Shah A, Khan S, Singh MM, Chauhan SC and **Jaggi M**. Induction of Autophagy by ormeloxifene and mevastatin through protein kinase D1 in prostate cancer cells. [105 American Association of Cancer Research \(AACR\) Annual Meeting 2014 \(April 5-9\), San Diego CA.](#)
 77. Sikander M, Zaman MS, Chauhan N, Yallapu MM, Khan S, Halaweish FT, Chauhan B, Kumari S, **Jaggi M** and Chauhan SC. A multi-targeted approach for pancreatic cancer treatment by a novel cucurbitacin analogue. [105 American Association of Cancer Research \(AACR\) Annual Meeting 2014 \(April 5-9\), San Diego CA.](#)
 78. Yallapu MM, Chauhan N, Othman SF, Khalilzad-Sharghi V, **Jaggi M** and Chauhan SC. Characterization of a novel magnetic nanoparticles formulation for cancer therapeutic applications. [105 American Association of Cancer Research \(AACR\) Annual Meeting 2014 \(April 5-9\), San Diego CA.](#)
 79. Chauhan N, Zaman MS, Maher DM, Ebeling MC, Yallapu MM, **Jaggi M** and Chauhan SC. Ormeloxifene inhibits cervical cancer cell growth through intrinsic apoptotic pathway. [105](#)

- American Association of Cancer Research (AACR) Annual Meeting 2014 (April 5-9), San Diego CA.*
80. Ganju A, Sundram V, Miskimins K, Gara R, Khan S, Singh MM, Chauhan SC and **Jaggi M**. Ormeloxifene attenuates metastatic and glycolytic pathways in breast cancer cells. *105 American Association of Cancer Research (AACR) Annual Meeting 2014 (April 5-9), San Diego CA.*
 81. Khan S, Ebeling M, Ansarullah, Chauhan N, Gara R, **Jaggi M**, Zhao H, Chauhan SC. Approach to enhance delivery and sensitivity of gemcitabine in pancreatic cancer by suppression of desmoplasia. *105 American Association of Cancer Research (AACR) Annual Meeting 2014 (April 5-9), San Diego CA.*
 82. Zaman MS, Chauhan N, Maher DM, Yallapu MM, **Jaggi M** and **Chauhan SC**. Curcumin nanoformulation. A new therapeutic approach for cervical cancer treatment. *105 American Association of Cancer Research (AACR) Annual Meeting 2014 (April 5-9), San Diego CA.*
 83. Yallapu MM., Ebleling MC., Khan S., Chauhan N., Gupta BK., Sundram V, **Jaggi M. and Chauhan SC**. Novel curcumin loaded magnetic nanoparticles for pancreatic cancer treatment. *104 American Association of Cancer Research (AACR) Annual Meeting 2013 (April 6-10), Washington DC.*
 84. Khan S., Maher D., Ebleling MC., Kumar D., **Jaggi M.** and Chauhan SC. MicroRNA-145 targets MUC13 and suppresses invasion and metastasis of pancreatic cancer cells. *104 American Association of Cancer Research (AACR) Annual Meeting 2013 (April 6-10), Washington DC.*
 85. Maher D., Bell M., Schaefer A., **Jaggi M.** and Chauhan SC. Benzo(a)pyrene exposure increases expression of HPV oncoproteins: a potential co-factor for increased cervical cancer among Northern Plains American Indian women. *104 American Association of Cancer Research (AACR) Annual Meeting 2013 (April 6-10), Washington DC.*
 86. Sundram V, Gara R., Singh MM., Chauhan SC and **Jaggi M**. Ormeloxifene modulates beta-catenin/TCF pathway in colon cancer. *104 American Association of Cancer Research (AACR) Annual Meeting 2013 (April 6-10), Washington DC.*
 87. Sundram V., Radel S., Hughes J., Singh MM., Chauhan SC. and **Jaggi M**. Suppression of prostate cancer growth and invasion by a triphenyl ethylene compound ormeloxifene. *103 American Association of Cancer Research (AACR) Annual Meeting 2012, Chicago, IL.*
 88. Yallapu MM., Othman SF., Curtis ET., Chauhan N., Bauer NA., **Jaggi M.** and Chauhan SC. Curcumin loaded magnetic nanoparticles for breast cancer therapeutics and imaging applications. *103 American Association of Cancer Research (AACR) Annual Meeting 2012, Chicago, IL.*
 89. Chauhan N., Maher DM., Yallapu MM., Ebeling MC., **Jaggi M.** and Chauhan SC. Therapeutic effects of ormeloxifene on cervical cancer. *103 American Association of Cancer Research (AACR) Annual Meeting 2012, Chicago, IL.*
 90. Maher DM., Stephenson P., Gupta BK., Bauer NA., Koch MD., Eliason S., **Jaggi M.** and Chauhan SC. Comparative expression profile of transmembrane mucin MUC1 in breast cancer from American Indian and Caucasian women. *103 American Association of Cancer Research (AACR) Annual Meeting 2012, Chicago, IL.*
 91. Gupta BK., Maher DM., Ebeling MC., Lynch DW., Koch MD., Puumala SE., Aburatani H., **Jaggi M.** and Chauhan SC. Role of MUC13 in colon cancer progression. *103 American Association of Cancer Research (AACR) Annual Meeting 2012, Chicago, IL.*

92. Sundram V., Chauhan SC. and **Jaggi M.** *Curcumin Modulates Protein Kinase D1 Signaling in Prostate Cancer*. Fourth International Conference on Translational Cancer Research. Rajasthan, India. **December 17, 2011.**
93. Gupta BK., **Jaggi M.** and Chauhan SC. Clinio-pathological significance of MUC13 mucin in colon cancer. Fourth International Conference on Translational Cancer Research. Rajasthan, India. **December 17, 2011.**
94. Hughes JE., Radel S., Sundram V., Jepperson TN., Koch MRD., Chauhan SC. and **Jaggi M.** Protein Kinase D1 expression attenuates colon cancer progression. **102 AACR Annual Meeting 2011**, Orlando, FL
95. Nordquist J., Maher DM., Ebeling M., **Jaggi M.** and Chauhan SC. Ormeloxifene treatment inhibits growth of cisplatin-resistant ovarian cancer cells. **102 AACR Annual Meeting 2011**, Orlando, FL
96. Gupta BK., Maher DM., Verma R., Ebeling M., Lynch D., Koch M., Watanabe A., Aburatani H., **Jaggi M.** and Chauhan SC. MUC13 expression enhances colon cancer progression. **102 AACR Annual Meeting 2011**, Orlando, FL
97. Yallapu MM., Othman SF., Curtis ET., Gupta BK., **Jaggi M.** and Chauhan SC. Multifunctional magnetic nanoparticles for theranostic applications. **102 AACR Annual Meeting 2011**, Orlando, FL
98. Yallapu MM., Ebeling M., Maher DM., **Jaggi M.** and Chauhan SC. Targeted curcumin delivery approach for improved prostate cancer therapeutics. **DOD IMPACT Meeting 2011**, Orlando, FL
99. **Jaggi M.**, Sundram V., Radel S. and Chauhan SC. Protein Kinase D1 suppresses B-catenin/T cell factor activity and attenuates prostate cancer growth. **DOD IMPACT Meeting 2011**, Orlando, FL
100. Dobberpuhl M., Yallapu MM., Maher DM., Gupta BK., **Jaggi M.** and Chauhan SC. Enhancing the efficacy of curcumin for prostate cancer treatment using cellulose nanoparticles. **8th International Nanomedicine and drug delivery systems-Omaha NanoDDS10**, Oct 3-5, Omaha, NE
101. Chauhan SC., Ebeling MC., Maher DM., Koch MRD., Friez MH. ⁴, Watanabe A., Aburatani Hiroyuki., Lio Y., Pandey KK and **Jaggi M.** MUC13 mucin augments pancreatic tumorigenesis. **101 AACR Annual Meeting 2010**, Washington DC
102. Nordquist J., Jaggi M and **Chauhan SC.** Effects of drug X on cisplatin-resistant and cisplatin-sensitive ovarian cancer cells. **21st Annual Meeting of the European Association for Cancer Research (EACR) 2010**. Oslo, Norway, June 26-29.
103. Maher D., Yallapu MM., Sundram V., Bell MC., **Jaggi M.**, Chauhan SC. Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. **101 AACR Annual Meeting 2010**, Washington DC.
104. Prakash Preethi., Freiz MH., Bohlmeier T., Koch MRD., Chauhan SC., **Jaggi M.** Downregulation of Protein Kinase D1 in hepatocellular carcinoma (HCC): Potential as a diagnostic/prognostic molecular marker. **101 AACR Annual Meeting 2010**, Washington DC.
105. Yallapu MM., **Jaggi M.**, Chauhan SC. Design of β -cyclodextrin-curcumin self-assembly: A new approach for enhanced curcumin delivery and therapeutic efficacy in prostate cancer cells. **101 AACR Annual Meeting 2010**, Washington DC.

106. Sundram V., Chauhan SC. and **Jaggi M.** Curcumin suppresses prostate cancer cells through modulation of β -catenin and protein kinase D1. *101 AACR Annual Meeting 2010*, Washington DC.
107. Jepperson . N, Tyler., Hughes J., Hausser A., Chauhan SC. and **Jaggi M.** Protein Kinase D1 reduces cellular proliferation and invasiveness via suppression of β -catenin/T-cell factor activity in SW480 colon cancer cells. AACR Centennial Meeting 2009, Denver, CO.
108. Prakash. P., Freiz. M., Bohlmeier, T., Chauhan SC. and **Jaggi M.** Differential expression of protein kinase D1 (PKD1) in various cancers and overexpression in thyroid cancer. AACR Centennial Meeting 2009, Denver, CO.
109. Maher DM., Bell MC., O'Donnell EA., **Jaggi M.**, Chauhan SC.. Curcumin inhibits the growth of cervical cancer cells and suppresses HPV oncoproteins E6 and E7. AACR Centennial Meeting 2009, Denver, CO.
110. Chauhan SC., Ebeling MC., Bell MC., Koch MD., Watanabe A., Aburatani H., Lio Y, Pandey KK., **Jaggi M.** Functional aspects of a membrane anchored mucin MUC13 in ovarian cancer. AACR Centennial Meeting 2009, Denver, CO.
111. Chauhan SC, Stangl CM., Christianson AB., Shearer GC., Harris WS. and **Jaggi M** Long Chain Omega-3-Fatty Acids (n-3 FA) Suppress Colon Cancer Cells Proliferation via Inhibition of β -catenin Transcription Activity . AACR Annual Meeting 2008, San Diego, CA
112. Chauhan SC., Yang J., Vinayek N., Koch MD., Harmon M., Bohlmeier T., **Jaggi M.** and Perryman MB. Deregulated expression of myotonic dystrophy protein kinase (DMPK) in cervical cancer. AACR Centennial Meeting 2007, Washington
113. Friez MH., Maher D., Vinayek N., **Jaggi M.**, Vannatta K., Watanabe A., Aburantani H., Koch RD., and Chauhan SC. Overexpression of transmembrane mucin MUC13 in pancreatic ductal adenocarcinoma. Pathology of the 21st Century Integrating Diagnostic and Molecular Pathology May 11-12, 2007, Houston Texas, USADC.
114. Maher D., Bell MC., **Jaggi M.**, and Chauhan SC. Natural Products for cervical cancer prevention and treatment. 2nd International Meeting on Translational Cancer Research and Natural Products 2007, Lonawala, India.
115. **Jaggi M.** and Chauhan SC. Bryostatin suppresses β -catenin transcription activity by PKD1 activation in prostate cancer cells 2nd International Meeting on Translational Cancer Research and Natural Products, 11-14 December, 2007, Lonawala, India.
116. Chauhan SC and **Jaggi M.** Cell signaling through mucins in cancer. Proceedings of South Dakota Academy of Science (PSDAS) 2007, Volume 86
117. Vannatta K., Vinayek N, Watanabe A, Dunham K, Bell MC, Koch MD, Aburatani H., **Jaggi M.** and Chauhan SC. MUC13 expression and its *in vitro* functions in ovarian cancer. *Proceedings of South Dakota Academy of Science (PSDAS) 2007, Volume 86*
118. Maher D., Bell M., Wattier K., Vannatta K., **Jaggi M.**, Srivastava S. and Chauhan SC. Inhibition of cervical cancer cell proliferation with chemopreventive agents and modulation of E-cadherin expression by I3C in cervical intraepithelial neoplasia AACR Centennial Meeting 2007, Washington DC.
119. Hughes J., Dunham K., Vinayek N., Cheng D., Balaji KC., Hausser A., Chauhan SC. and **Jaggi M.** Modulation of β -catenin/T cell by protein kinase D1 in SW 480 colon cancer cells. AACR Centennial Meeting 2007, Washington DC.

120. Vinayek N., Dunham K., Wattier K., Koch MD., Chauhan SC. and **Jaggi M.** Differential expression of cadherins and catenins in gynecological cancers. AACR Centennial Meeting 2007, Washington DC.
121. Vinayek N., Vannatta K., Watanabe A., Dunham K., Bell M C., Koch MD., Aburatan H., **Jaggi M.** and Chauhan SC. Aberrant expression of a transmembrane mucin MUC13 in ovarian cancer. 7th Joint Conference of the AACR- Japanese Cancer Association: *In the Forefront of Basic and Translational Cancer Research*, 2007 January 21-25, Waikola, Hawaii.
122. Dunham K., Vinayek N., Hughes J., Balaji KC., Chauhan SC. and **Jaggi M.** Effect of Protein Kinase D1 on β -catenin transcription activity and cell cycle in prostate cancer cells. 7th Joint Conference of the AACR- Japanese Cancer Association: *In the Forefront of Basic and Translational Cancer Research*, 2007 January 21-25, Waikola, Hawaii.
123. Dunham K., Vinayek N., Cheng D., Balaji KC., Hausser A., Chauhan SC. and **Jaggi M.** Modulation of β -catenin/T cell by protein kinase D1 in SW 480 colon cancer cells. (Presented at AACR Centennial Meeting 2007).
124. Chauhan SC, Stangl CM., Christianson AB., Shearer GC., Harris WS. and **Jaggi M** Long Chain Omega-3-Fatty Acids (n-3 FA) Suppress Colon Cancer Cells Proliferation via Inhibition of β -catenin Transcription Activity . *AACR Annual Meeting 2008*, San Diego, CA
125. Chauhan SC., Yang J., Vinayek N., Koch MD., Harmon M., Bohlmeier T., **Jaggi M.** and Perryman MB. Deregulated expression of myotonic dystrophy protein kinase (DMPK) in cervical cancer. *AACR Centennial Meeting 2007*, Washington DC.
126. Friez MH., Maher D., Vinayek N., **Jaggi M.**, Vannatta K., Watanabe A., Aburantani H., Koch RD., and Chauhan SC. Overexpression of transmembrane mucin MUC13 in pancreatic ductal adenocarcinoma. *Pathology of the 21st Century Integrating Diagnostic and Molecular Pathology* May 11-12, 2007, Houston Texas, USA
127. Maher D., Bell MC., **Jaggi M.**, and Chauhan SC. Natural Products for cervical cancer prevention and treatment. *2nd International Meeting on Translational Cancer Research and Natural Products 2007*, Lonawala, India.
128. **Jaggi M.** and Chauhan SC. Bryostatin suppresses β -catenin transcription activity by PKD1 activation in prostate cancer cells *2nd International Meeting on Translational Cancer Research and Natural Products*, 11-14 December, 2007, Lonawala, India.
129. Vinayek N., Dunham K., Wattier K., Koch MD., Chauhan SC. and **Jaggi M.** Differential expression of cadherins and catenins in gynecological cancers. (Presented at AACR Centennial Meeting 2007).
130. Chauhan SC., Yang J., Vinayek N., Koch MD., Harmon M., Bohlmeier T., **Jaggi M.** and Perryman MB. Deregulated expression of myotonic dystrophy protein kinase (DMPK) in cervical cancer (Presented in AACR Centennial Meeting 2007).
131. Maher D., Bell M., Wattier K., Vannatta K., **Jaggi M.**, Srivastava S. and Chauhan SC. Inhibition of cervical cancer cell proliferation with chemopreventive agents and modulation of E-cadherin expression by I3C in cervical intraepithelial neoplasia (Presented in AACR Centennial Meeting 2007).
132. Vinayek N., Vannatta K., Watanabe A., Dunham K., Bell M C., Koch MD., Aburatan H., **Jaggi M.** and Chauhan SC. Aberrant expression of a transmembrane mucin MUC13 in ovarian cancer. 7th Joint Conference of the AACR- Japanese Cancer

Association: In the Forefront of Basic and Translational Cancer Research, January 21-25, Waikola, Hawaii.

133. Dunham K., Vinayek N., Hughes J., Balaji KC., Chauhan SC. and **Jaggi M.** Effect of Protein Kinase D1 on β -catenin transcription activity and cell cycle in prostate cancer cells. 7th Joint Conference of the AACR- Japanese Cancer Association: *In the Forefront of Basic and Translational Cancer Research*, January 21-25, Waikola, Hawaii.
134. Chauhan SC., Vinayek N., Dunham K., Lio Y., Koch MD. and **Jaggi M.** Analysis for MUC1, MUC16 and TAG-72 expression in ovarian cancer: Antigens of multi-targeted antibody guided therapy. 2006 AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development, September 12-15, Chicago, IL
135. **Jaggi M.** and Balaji .K. C. Protein kinase D1 is associated with membrane trafficking of β -catenin; 2006 Proc Amer Ass Can Res, Poster presentation.
136. Balaji K.C., Rao Prema S, **Jaggi M.** Lynette M. Smith and David J. Smith. Induction of Metallothioneins is Associated with Resistance to Cisplatin and Radiation in Prostate Cancer Cells; 2005 Proc Amer Ass Can Res, Poster presentation.
137. **Jaggi M.** and Balaji. K.C. Beta-catenin Interaction with PKD1/PKC Mu and Nuclear Localization in Prostate Cancer; 2005 Prostate Cancer Symposium, American Society of Clinical Oncology, Orlando, FL, 2/2005, Poster presentation.
138. **Jaggi M.**, Nazemi T. and Balaji K.C. Aberrant Expression of N-cadherin Correlates with Gleason Grade and Preoperative Serum Prostate Specific Antigen (PSA) in Prostate Cancer 2005 Prostate Cancer Symposium, American Society of Clinical Oncology, Orlando, FL, 2/2005, Poster presentation.
139. **Jaggi M.** and Balaji. K.C. E-cadherin Phosphorylation by PKD1/PKC Mu is Associated with Altered Cell Aggregation and Motility in Prostate Cancer; 2005 Prostate Cancer Symposium, American Society of Clinical Oncology, Orlando, FL, 2/2005, Poster presentation.
140. **Jaggi M.**, Nazemi T and Balaji K.C. Bryostatin-1 Activates PKD1 and Increases Cellular Aggregation in Prostate Cancer; 2005 Prostate Cancer Symposium, American Society of Clinical Oncology, Orlando, FL, 2/2005, Poster presentation.
141. Rao P. S, Tamra L, Smith D. J., **Jaggi M.**, Balaji K.C, and Hemstreet G P. Protein Kinase C μ Protein Kinase D – Metallothionein 2A Interaction is Associated with Cisplatin Resistance in Prostate Cancer, SCS, AUA, 83rd annual meeting, Dublin, Ireland, Poster #14, 9/04.
142. Lewis T, Milam T, Rao P S., **Jaggi M.**, Smith D.J. George P. Hemstreet, and Balaji K.C.. Tissue Transglutaminase Interacts with a Kinase Anchor Protein 13 in Prostate Cancer, SCS, AUA, 83rd annual meeting, Dublin, Ireland, Poster #11, 9/04
143. **Jaggi M.**, Hemstreet G P, and. Balaji K.C. Aberrant Expression of E-Cadherin, N-Cadherin and Beta-Catenin in Human Prostate Cancer (PC), SCS, AUA, 83rd annual meeting, Dublin, Ireland, Poster #41, 9/04.
144. **Jaggi M.**, Hemstreet G P., and Balaji K.C.. Protein Kinase C MU (PKC MU) Interacts with E-Cadherin and Beta-Catenin in Prostate Cancer (PC) In Vitro and In Vivo, SCS, AUA, 83rd annual meeting, Dublin, Ireland, ABS #21, 9/04.
145. **Jaggi M.** Rao P S., Smith D J., Hemstreet G P, and. Balaji K.C. Protein Kinase C Mu (PKC Mu) interacts with E-cadherin and Beta-catenin in Prostate Cancer in vitro and in vivo. Proc Amer Ass Can Res, Vol. 45, Abs. 5147, 2004.

146. **Jaggi M.**, Johansson S. L., Baker J J., Rao P S, Smith D J., Hemstreet G P., and Balaji K.C. Aberrant Expression of E-cadherin, N-cadherin and Beta-catenin in Human Prostate Cancer Proc Amer Ass Can Res, Vol. 45, Abs. 2675, 2004.
147. Smith D J., **Jaggi M**, Rao P S., Hemstreet G. P, and Balaji K.C.. A DNaseI Hypersensitive Site in the Promoter Region of the Human PKC Mu Gene. Proc Amer Ass Can Res, Vol. 45, Abs. 1577, 2004.
148. Rao. P S., **Jaggi M** and. Balaji K.C. Protein Kinase C Mu (PKC Mu) interacts with metallothionin2-A in prostate cancer. SCS, AUA, 82nd Annual meeting, Boston, MA, Abs. 97, 2003.
149. **Jaggi M.**, Balaji K.C, Wheelock M J., and K R. Johnson. Activation of PKC by phorbol ester results in the formation of adherens junction in MDA-MB-453 cells. Proc Amer Ass Can Res, Vol 44, Abs 1390, 2003.
150. **Jaggi M.**, Wheelock M. J.and. Johnson K.R. Differential displacement of classical cadherin by VE- cadherin. Proc. The American society for cell biology, 41 Annual meeting, Washington D C. Dec.2001.
151. **Jaggi M**, Basak S.and Das C. Hormonal regulation of integrins statement in mouse blastocyst during implantation. Proc. VII International Congress of Reproductive Immunology, New Delhi, Oct 27-30 1998.
152. S. Basak, **Jaggi M** and. Das C. Stage specific statement of integrins in mouse blastocyst during implantation. Proc. VII International Congress of Reproductive Immunology, New Delhi, Oct 27-30 1998.
153. **Jaggi M**, S. Basak and C. Das. Modulation of integrin statement by steroid hormones in mouse blastocyst .The 10th International Congress of Immunology, New Delhi, 1-6 Nov. 1998.
154. **Jaggi M.**, Murthy P.S. R and Mehrotra P.K. statement of cytokeratin and Vimentin in first trimester human placenta villi. Proc. International Conference. On reproductive Health, Bombay, March 1998.
155. **Jaggi M.** and. Mehrotra P.K. First trimester human trophoblasts in culture to test pregnancy interceptive in vitro. Proc. Young Scientist Symposium on Reproductive Health Issues, Gujarat, 24-26 May1997.
156. **Jaggi M.**, Mehrotra P.K, Maitra S.C., Agarwal S.L and. Das. K. Gestation age dependent changes in surface morphology of human chorionic Villi during early pregnancy. Proc. International Symposium on Prospects of Zona Pellucida Glycoproteins for Immunocontraception and 7th Annual Conference of Indian Society for the Study of Reproduction and Fertility, New Delhi, 2-5 December 1995.
157. **Jaggi M**, Mehrotra P.K., Maitra S.C., Agarwal S. L, Das K.and. Kamboj V.P. Ultrastructure of cellular Components of human trophoblasts during early pregnancy. **Placenta** (1994), Vol. 15A.34.
158. **Jaggi M.**, Maitra S.C., Agarwal S.L., Das K and Mehrotra P.K. Ultrastructure of human trophoblasts of first trimester chorionic Villi. Proc. at the National Symposium on Reproductive Health Care, Jaipur, (1994), 4-6 February.
159. **Jaggi, M.** Maitra S.C, Agarwal S. L., Das K and. Mehrotra P.K. Surface morphology of early gestation human placental Villi. Proc. Endocrine Society of India, ESICON, Pondicherry, 1-3 December 1994

PATENT APPLICATIONS AND AWARDS:

1. Applied for four US Provisional Patents for developing a novel anti-cancer drug and one patent is already approved (PCT/US2011/063723).
2. One product is pending for technology transfer to Advance Orthomolecular Research (a Canada based company)

CONSULTATION ACTIVITIES:

Grant Review Panel:



OTKA. (Reviewer for the grant proposal submitted to the Hungarian Scientific Research Fund (OTKA).

2014 West Cancer Intramural Grant review panel

Contribution to Science

Defining Role of PKD1 as a Tumor Suppressor in Prostate Cancer: My publications, for the first time, elucidated the role of Protein Kinase D1 (PKD1), as a tumor suppressor in prostate cancer. My seminal work has shown that PKD1 is down-regulated in advanced stage metastatic prostate cancer and there are reasons to believe that down-regulation of PKD1 in prostate cancer leads to not only transition of castrate dependent prostate cancer to castrate independent prostate cancer but also mediates aggressiveness of prostate cancer. Our publications (**Fig. 1**) elucidated the molecular mechanism for interaction of PKD1 with β -catenin/E-cadherin leading to interaction, phosphorylation and translocation of β -catenin from cytoplasm and nucleus to membrane leading to activation of E-cadherin signaling. Re-localization of nuclear β -catenin is responsible for inhibition of epithelial mesenchymal transition (EMT) leading to cell retaining epithelial characteristics, being less motile and increasing cell-cell aggregation and communication. These publications document that PKD1 can be used as a diagnostic and prognostic marker for prostate cancer but also provide clinical approaches whereby increasing PKD1 expression by PKD1 modulators such as ormeloxifene, curcumin and Bryostatin-1 can inhibit metastatic characteristics of prostate cancer cells. Further, my work established that PKD1 and β -catenin interaction do play a role in colon cancer where in 80% of cases due to APC mutation, β -catenin expression/localization is highly deregulated leading to down-regulation of PKD1. Publications arising from my work will provide assistance in relevant medical settings well into the future. I served as primary/lead investigator in all of these studies.

Link for other related Publications:



<http://www.ncbi.nlm.nih.gov/pubmed/?term=Meena+Jaggi%2C+PKD1>

Defining Oncogenic Roles of MUC13 in Cancer Progression:



In addition to contributions described above, with a team of collaborators, our group has identified a novel transmembrane protein mucin 13 (MUC13), which is aberrantly expressed in ovarian, colon and pancreatic cancers and can serve as an early cancer marker and potential therapeutic target for antibody therapy. These studies emphasize the role of MUC13 in pancreatic, colon and ovarian cancer tumorigenesis and metastasis. These studies have also elucidated that MUC13 also play a role in chemoresistance in advanced stage pancreatic cancer cells. This body of work will be relevant for pancreatic cancer treatment and how relevant medical setting can use this body of work to mitigate the effect of this disease and reduce the cancer burden. I have served as a senior co-Investigator in all of these studies.

Link for other related Publications:

<http://www.ncbi.nlm.nih.gov/pubmed/?term=Meena+Jaggi%2C+mucin>

Generation of Novel Nanoparticle Formulations for Cancer Treatment: My other research is focused on formulation of nanoparticles for new and used chemotherapeutic drug for treatment of different cancer cells. The main aim of this research work is to applying drug delivery applications for cancer therapeutic purpose. Research work from our collaborative work has demonstrated effectiveness of nanoparticle formulation of curcumin which our group has patented (Curcumin Formulations and methods for making such formulations, Filing No. 61/365,946 Filing Date: Jul 15, 2011 Issue Date: Aug. 14, 2014, Publication Number: US2014/0228318 A1) and other formulation while are still in process of being patented. These studies demonstrate the commercial aspect of these nanoformulations. I have been lead co-Investigator in these studies.

Link for other related publications:



<http://www.ncbi.nlm.nih.gov/pubmed/?term=Meena+Jaggi%2C+nanoparticles>